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ABSTRACT 
SYKES, JEAN CRANE, Ph.D. Progesterone response of females 
participating in a progressive running program. (1986). 
Directed by Terry L. Bazzarre, Ph.D. 167 pp. 
To assess plasma progesterone (P) response to progressive exer­
cise, 17 female recreational runners participated in a study spanning 
7 menstrual cycles. Control subjects (C) (n=8) maintained their usual 
physical activity at baseline levels (14-19 mi/week), while experimen­
tal subjects (E) increased their average mileage from 20 to 32 
mi/week. Blood samples drawn every other day during the 1st and 7th 
menstrual cycles, beginning on Day 10 of each cycle, were analyzed for 
luteinizing hormone and P. Activity and diet records for Days 3-10 of 
the 1st, 3rd, 5th, and 7th menstrual cycle provided estimates of 
energy balance. Coinciding with these records were 24-hr urine 
samples, which were analyzed for 3methylhistidine (3-MH). Subjects 
consumed a lacto-ovo vegetarian diet required for measurement of 
3-MH. Among E subjects, the median number of days in which P con­
centration was greater than 6.0 ng/ml declined from 5.0 days at the 
1st menstrual cycle to 0.0 days by the 7th cycle (p< .05). A signifi­
cant decrease in the P-vs-time area under the curve was observed among 
C subjects (JD< .05). There were no statistically significant differen­
ces between C and E with respect to the degree of change in P con­
centrations, suggesting that the progressive exercise of the E 
subjects was not responsible for alterations in P. All subjects 
maintained relatively constant body weight and fat levels. No 
evidence of energy deficit or protein inadequacy was apparent from 
dietary analyses, estimates of energy expenditure, or from values of 
urinary 3-MH excretion. Results of the study suggest that some uni­
dentified factor (possibly dietary) influenced menstrual function 
among these female runners. A more rapid progression of exercise, as 
well as a more in-depth exploration of dietary variables is recom­
mended for future research. 
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CHAPTER I 
INTRODUCTION 
Women have become increasingly active in sports and exercise 
activities in recent years. Since the passage of Title IX of the 
Education Amendments Act of 1972 (Bodnar & Bodnar, 1980), there have 
been more opportunities for women to participate in sports. There has 
been a growing sense of societal acceptance of female athleticism, as 
well as greater recognition of the physical and athletic abilities of 
women. Encouraging women to become more physically active has been 
an emerging interest of society in preventive health care. 
As a result of the increased participation of women in sports 
and exercise activities, greater attention has been focused on the 
relationship between physical activity and female reproductive 
function. Investigations of exercise-related menstrual irregularities 
and athletic amenorrhea have led to a better understanding of the 
phenomenon; however, the etiological mechanisms remain obscure. 
The initial objective of the present study was to test the 
assumption that reproductive hormone function is affected by a 
progressively vigorous running program over a period spanning 7 
menstrual cycles. Fulfilling that assumption, the hypotheses to be 
tested were as follows. 
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Among females showing evidence of menstrual dysfunction secon­
dary to exercise training (as indicated by alterations in reproductive 
hormone concentrations): 
1. There is a greater energy drain (ratio of energy expenditure 
to energy intake) than among eumenorrheic females participating in a 
similar exercise program. 
2. There is a higher prevalence of negative protein balance 
than in eumenorrheic females in a similar program. 
3. There is a negative correlation between energy drain and 
hypothalamic and pituitary function, as indicated by urinary 
luteinizing hormone. 
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CHAPTER II 
REVIEW OF LITERATURE 
To help clarify the distinction between normal menstrual status 
and that of oligo- and amenorrheic athletes, the following review of 
literature was developed. This review includes an overview of 
menstrual physiology as well as a description of the criteria that 
have been used to define eumenorrhea, oligomenorrhea, and amenorrhea. 
Following this background information is a description of the hormonal 
characteristics reported to be associated with exercise-related 
menstrual disturbances. 
Various estimates of the prevalence of exercise-associated 
menstrual irregularities are summarized, and the potential ramifica­
tions of oligomenorrhea and amenorrhea are discussed. Finally, the 
mechanisms that have been proposed to explain the development of 
exercise-related menstrual irregularities are reviewed. 
Overview of Menstrual Physiology 
The menstrual cycle consists of two phases: follicular and 
luteal. The follicular phase begins on the first day of menstruation 
(Day 1 of the cycle) and extends until ovulation. The follicular 
phase is so named because of the presence of the ovarian follicle, 
which is the structure containing the ovum. (Numerous follicles 
respond to hormonal stimulation for growth and development, but 
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usually only one follicle survives to ovulate, the "dominant" follicle 
that matures most rapidly.) After expulsion of the egg at ovulation, 
the remains of the ovarian follicle is called a corpus luteum; hence 
the name "luteal" for the second phase of the cycle. The luteal phase 
begins at ovulation and lasts until Day 1 of the next menstrual cycle. 
There are distinct hormonal patterns associated with each phase 
of the menstrual cycle. The pituitary hormones luteinizing hormone 
(LH) and follicle-stimulating hormone (FSH) play an essential role in 
the development of menstrual events. These two glycoproteins are 
regulated by gonadotropin-releasing hormone (GnRH), a decapeptide that 
is produced and secreted by the hypo thalamus. 
During the early follicular phase, the primary functions of FSH 
are to promote follicular maturation, and to cause estrogen synthesis 
(Shangold, 1984). The estrogen precursors are androgens originating 
in the theca cells of the follicle, production of which is regulated 
by LH. The androgens migrate to the granulosa cells where FSH causes 
aromatization (McNatty, Makris, DeGrazia, Osathanondh, 5 Ryan, 1979). 
The rising estrogen concentration resulting from aromatization within 
the granulosa cells fosters the development of FSH receptor sites on 
the granulosa cells. Circulating levels of estrogen modulate GnRH and 
gonadotropin production critical to follicular development (Speroff, 
Glass, 5 Kase, 1983, chap. 3). 
The estrogen concentration of the dominant follicle (probably 
the follicle that is most mature) continues to rise. Locally, the 
high estrogen concentration further promotes the development of 
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FSH receptors. Thus, despite a fall in circulating FSHt the con­
centration of the hormone remains high within the follicle. The 
decrease in plasma FSH levels is attributable to the high estrogen 
levels. With fewer FSH receptor sites, the less-developed follicles 
begin to degenerate, leaving the dominant follicle to thrive in the 
estrogen-rich microenvironment it is able to sustain for itself 
(Speroff et al., 1983, chap. 3). 
There is a pronounced rise in estrogen concentrations just prior 
to ovulation, which initiates the midcycle LH surge. This abrupt ele­
vation of LH triggers an increase in follicular progesterone produc­
tion, which is evident as a small but significant rise in circulating 
progesterone levels 12-24 hours before ovulation (Moghissi, Syner, 5 
Evans, 1972). The progesterone surge is believed to initiate a less 
precipitous surge in FSH (Shaw, Butt, 8 London, 1975), the signifi­
cance of which is poorly understood. The high LH concentrations late 
in the follicular phase stimulate ovulation, the rupture of the 
follicle and expulsion of the ovum. 
The remains of the follicle undergo histologic changes, forming 
the corpus luteum. The corpus luteum is capable of secreting large 
quantities of both estrogen and progesterone, which peak about 8 or 9 
days postovulation. Estrogen's primary function is to cause proli­
feration of the endometrium, the lining of the uterus. Progesterone 
helps to further prepare the endometrium for implantation of a fer­
tilized ovum. The lifespan of the corpus luteum is dependent on its 
capacity for steroid synthesis, which, in turn, is dependent upon 
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tonic LH secretion (Speroff et al., 1983, p. 92). Gonadotropin release 
is inhibited by the high concentrations of estrogen and progesterone 
during the luteal phase (Shangold, 1984). In the absence of fer­
tilization, the corpus luteum begins to degenerate 9-11 days after ovu­
lation, the mechanism of which is unknown. (If the ovum is fertilized, 
human chorionic gonadotropin maintains steroidogenesis until placental 
steroidogenesis is established in the 9th or 10th week of gestation.) 
With the decline of the corpus luteum, estrogen and progesterone levels 
fall. Progesterone withdrawal results in the degeneration of the endo­
metrium, resulting in menstruation. Gonadotropin levels, especially 
FSH, then start to rise, initiating another menstrual cycle. 
Definitions of Normal Menstruation and 
of Oligo- and Amenorrhea 
When menarche has not occurred by the age of 16, primary ame­
norrhea is diagnosed, whereas cessation of menstrual cycles in women 
who have previously menstruated represents secondary amenorrhea. 
There is a departure from consensus beyond this level of defining 
amenorrhea. Indeed, there has not always been agreement on what con­
ditions represent normal (eumenorrheic) or irregular (oligomenorrheic) 
menstrual status. A eumenorrheic pattern has been described by Loucks 
and Horvath (1985) as menstrual cycles occurring at consistent inter­
vals ranging from 25-38 days, with regularity more important than the 
absolute length of the intervals. Similarly, Loucks and Horvath point 
out that a 39-90-day interval used to define oligomenorrhea is an 
arbitrary limitation; that a key characteristic of oligomenorrhea is 
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inconsistency of menstrual cycles. In other words, by these defini­
tions, a woman whose menstrual cycles recur at consistent intervals of 
40 days would be classified as eumenorrheic. 
Absence of menstruation for 6 months or more is accepted by some 
authorities as constituting amenorrhea (Frisch et al., 1981; A.D. 
Rogol, personal communication, December 15, 1985; Speroff et al., 1983, 
p. 142). Ninety or more days with no menses is also frequently used as 
a defining criterion of amenorrhea (Bachmann 8 Kemmann, 1982; 
Petterson, Fries, S Nillius, 1973; Sanborn, Martin, 5 Wagner, 1982; 
Yen, 1978). 
Amenorrhea has been classified according to diagnostic procedures 
(Ross, Vande Wiele, 5 Frantz, 1981; Speroff et al., 1983, chap. 5). 
For the purpose of this paper, however, a more useful system of classi­
fication is the pathophysiological model provided by Yen (1978). Yen 
categorizes amenorrhea by underlying cause: (a) anatomic cause, (b) 
ovarian failure, and (c) chronic anovulation. Examples of anatomic 
causes include endometrial adhesions and abnormal differentiation of 
the genital tract. Ovarian failure includes gonadal dysgenesis and 
"gonadotropin-resistant ovaries" (probably due to insufficient ovarian 
gonadotropin receptor sites). These amenorrheic women typically exhi­
bit hypergonadotropinism. 
Chronic anovulation syndrome, the most common type of amenorrhea, 
is the category in which athletic amenorrhea belongs (Loucks 6 Horvath, 
1985). In women with this disorder, the administration of estrogen 
followed by progesterone for the appropriate number of days produces 
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withdrawal bleeding, suggesting that the ovaries are at least minimally 
functional (Speroff, et al.( 1983, chap. 5). The mechanism of the ame­
norrhea involves either the hypothalamic-pituitary axis or disturbances 
in the peripheral metabolism of steroid hormones (Yen, 1978). Yen 
further categorizes chronic anovulation syndrome according to the site 
of the defect: 
1. Hypothalamic chronic anovulation: Characterized by abnormal 
GnRH release due to a defect in the CNS-hypothaiamic unit. 
2. Pituitary chronic anovulation: Disturbance in gonadotropes 
resulting from either impairment of the synthesis of the gonadotropin 
<*-/3 subunit or from abnormalities in gonadotropin receptor sites. 
3. Inappropriate feedback: (a) abnormal sex steroid levels due 
to steroid therapy or to androgen or estrogen-producing tumors, (b) 
excessive extraglandular estrogen or androgen production, and (C) 
abnormal buffering system (alterations in sex-hormone binding globulins 
or in interconversions between steroids). 
4. Other endocrine or metabolic dysfunctions: (a) Excessive 
Cortisol and/or androgen production (Cushing's disease and syndrome), 
(b) hyper- and hypothyroidism, (c) prolactin or growth hormone excess, 
and (d) malnutrition. 
Prevalence of Athletic Amenorrhea 
Reports of the prevalence of athletic amenorrhea have varied 
widely, depending on the population surveyed, and upon the definition 
of amenorrhea used by investigators. In a study of 128 college track 
and field or cross-country runners, the frequency of amenorrhea 
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(defined as 3 or fewer cycles per year) was 6% among women who ran 
less than 10 miles per week, and as high as 43% among runners who 
trained more than 60 miles per week (Feicht, Johnson, Martin, Sparkes, 
5 Wagner, 1978). Using the defining criterion of at least 3 months 
with no menses, Calabrese et al. (1983) reported that 44% of 34 classi­
cal ballet dancers were amenorrheic. Sanborn et al. (1982) observed a 
higher prevalence of amenorrhea among 237 runners (25.7%) than among 
swimmers (12.3%) or cyclists (12.1%). Other studies of athletes in 
general, and of runners, have reported prevalence rates ranging from 
3.4 to 12.1% (Carlberg, Buckman, Peake, 8 Riedesel, 1983b; Lutter 5 
Cushman, 1982; Schwartz et al., 1981; Speroff 5 Redwine, 1980). The 
lower prevalence of 3.4% reported by Lutter and Cushman is a reflection 
of their stringent definition of amenorrhea of at least 12 months dura­
tion with no menses. 
Investigations of the prevalence of secondary amenorrhea in the 
general population have yielded more consistent results of approxima­
tely 3% (2.6-3.3%) (Bachmann & Kemmann, 1982; Carlberg et al., 1983b; 
Petterson et al., 1973). These researchers all defined amenorrhea as a 
minimum of 3 months with no menses. 
Although the lack of menstruation can be determined by survey 
questionnaire, the prevalence of menstrual irregularities is virtually 
impossible to accurately assess by questionnaire. A number of investi­
gators have reported evidence of a shortened luteal phase among ath­
letes whose menstrual cycles appear otherwise normal (Bonen, Belcastro, 
Ling, 5 Simpson, 1981; Jacobson 5 Bonen, 1981; Jacobson, Wilkinson, 
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8 Bonen, 1983; Prior, Cameron, Yuen, 8 Thomas, 1982; Shangold, Freeman, 
Thyson, 8 Gatz, 1979). Such information would go undetected by a sur­
vey or interview, as it can only be ascertained via evaluating 
athletes' hormone profiles (Bonen 8 Keizer, 1984). Consequently, pre­
valence rates documented by survey methodology are likely to be an 
under representation of the degree of menstrual irregularities among 
athletes. Basal body temperature is sometimes used as an indicator of 
ovulation (Collett, Wertenberger, 5 Fiske, 1954; Frisch et al., 1981; 
Prior et al., 1982), but even these data can appear normal despite 
abnormal luteal function (Ross et al., 1981). 
Relevance of the Study of Athletic Amenorrhea 
The immediate effects of amenorrhea and chronic anovulation on 
fertility are obvious. If for no other concern than fertility, ath­
letic amenorrhea warrants investigation. The long-term effects are 
less clear. The first published evidence of a potential harmful effect 
directly attributable to athletic amenorrhea was reported by Cann, 
Martin, and Genant (1982). They studied 25 amenorrheic women, 6 of 
whom were runners with diagnosed hypothalamic amenorrhea. The 
remainder of subjects were nonrunners with amenorrhea due either to 
ovarian failure or to hyperprolactinemia secondary to prolactinomas. 
Bone mass of all of the amenorrheic women, including runners, was 28% 
less than that of 45 age-matched controls, suggesting that women with 
secondary amenorrhea have an increased risk of developing osteoporosis. 
More recent studies have confirmed these early findings in athletes 
(Cann, Martin, Genant, 8 Jaffe, 1984; Drinkwater et al., 1984; 
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Lindberg et al., 1984; Linnell, Stager, Blue, Oyster, 5 Robertshaw, 
1984; Marcus et al., 1985). 
Reversibility of athletic amenorrhea has been difficult to study, 
since most athletes are not receptive to the suggestion that they cease 
or moderate their current training regimen or that they gain weight, 
two recommendations generally believed to be associated with resumption 
of menses ("Impact of exercise," 1982; Speroff et al., 1983, p. 177). 
Reversibility of amenorrhea as well as reversion back to an amenorrheic 
state has been observed in ballet dancers. Abraham, Beumont, Fraser, 
and Llewelyn-Jones (1982) categorized 29 ballet students as (a) eume-
norrheic (menstrual cycle interval of 25-34 days), (b) irregular 
(interval of 14-24 or 35-46 days), (c) oligomenorrheic (interval of 
7-11 weeks), or (d) amenorrheic (no menses for 3 or more months). Each 
subject's menstrual pattern was followed for one year. Improvement in 
menstrual status was defined as a change of at least one category 
toward regular menstruation. During periods of 4 or more weeks of 
decreased physical activity (vacation or injury), 19 out of 21 dancers 
showed improvement in menstrual status. 
Warren's study of 13-15-year-old ballet dancers (1980) revealed 
similar findings. The progression of pubertal development increased, 
and the prevalence of amenorrhea decreased with reduced physical acti­
vity of 2 months or more. Dancers have reported more frequent 
menstruation during vacations or when not dancing than during periods 
of heavy physical activity (Abraham et al., 1982; Calabrese et al., 
1983). 
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Although athletic amenorrhea may be reversible, it is not known 
if reproductive function is permanently affected, or if there is a 
period of time beyond which an amenorrheic state cannot be reversed to 
restore reproductive function. Stager, Ritchie-Flanagan, and 
Robertshaw (1984) detected no relationship between the length of time 
of amenorrhea and the time required to regain normal periodicity in 
their survey of former college runners. No women reported more than 6 
months as the time for normal periodicity to return after training 
cessation, and the mean time was 1.7 months. 
O'Herlihy (1982) described two amenorrheic runners who did not 
respond to 5 days of clomiphene citrate administration. Ovulation was 
achieved in both runners, however, using half the dosage of the pre­
viously ineffective drug, administered within 6 and 8 weeks of running 
cessation; one woman conceived during that first ovulatory cycle. 
Hormone Evaluation in Oligo- and 
Amenorrheic Athletes 
There have been conflicting reports of hormone profiles among 
athletes with menstrual irregularities. Many of the discrepancies 
reported in the literature may be attributed to poor research design 
or implementation, as well as the lack of standard defining criteria 
for oligo- and amenorrhea. The following section is a review of 
endocrine research relative to the study of athletic amenorrhea. 
A summary of basal endocrine results of studies of amenorrheic ath­
letes is included in Table I. 
Luteinizing Hormone. Comparisons of basal LH concentrations 
among amenorrheic and normally menstruating athletes have yielded 
Table 1 
Comparisons of Endocrine Profiles of Amenorrhelc Runners with Eumenorrhelc Runners or Nonathletes°t 
Reference Sample and Comment LHfmlU/ml FSH,mlU/ml E2,pg/ml P,ng/ml Other 
Baker et at. 
(1981) 
McArthur et al, 
(1980) 
-14 cyclic (EUM) EUM 
-9 amenorrhelc (AM) AM 
-{3 of 9 became AM 
during study) 
-1 sample/cycle 
-Cycle phase of sample 
not reported 
-6 cyclic nonathletes (NA) NA 
-3 amenorrhelc (AM) AM 
-Serial sampling for 4 
hr (15-mln interval) 
9.7+1.0 
6.5+1.0 
([>571)5) 
2.1+0.3 
0.6+D.3 
8.0+0.6 
7.6+D.8 
(US) 
3.8+0.7 
2.7+D.2 
58.0+8.0 
20.0+6.0 
(̂ <70*05) 
-NS differences 
for: DHEA, 
DHEAS, A, T, 
PRL 
Richards 
(1985) 
et al, 
Schwartz et al. 
(1981) 
Veldhui s et al, 
(1985) 
-5 cyclic nonathletes (NA) NA 1.7+0.5 10.8+1.7 
-7 eumenorrhelc (EUM) EUM 3.3+3.8 8.7+2.1 
-8 amenorrhelc (AM) AM 1.5+0.6 9.2+1.2 
-Midfol I Icular sampling: (TI5) ((45) 
1/hr for 24 hr 
-EUM ran 39 MPW 
-AM ran 35 MPW 
-20 cyclic nonathletes (NA) 
-25 eumenorrhelc (5-30 MPW) 
(Middle distance) 
-41 eumenorrhelc (>30 MPW) 
(Long distance) 
-12 amenorrhelc (AM) 
-1 early folIicular 
sample 
-Exact hormone values 
not reported 
-10 cyclic nonathletes (NA) NA 8.0+1.4 
-9 amenorrhelc (AM) AM 6.6+5.5 
-Early follicular serial 
sampling: 24 hr (20-
mln Intervals) 
105.4+46.3 
142.7+147.2 
97.4+23.5 
(NST 
t In AM vs. NS 
distance difference 
runners or 
NA (£<.05) 
80.9+11.0 
52.$n.5 
<1.0 
<1.0 
(NA) 
NS differences 
for PRL, T, TSH 
4 9.5+1.8* 
EUM 8.3+2.1 
AM 7.3T1.2* 
*(p<.TJ5) 
-NS differences 
for: DHEAS, A, 
T, E,, E, 
-EJ:E2 ratio: 
t in runners vs. 
NA (p<.01) 
-TSH: 4 In AM vs. 
all others (p<.05) 
-NormaI vaIues 
for T and thyroid 
function In AM 
"All subjects were runners except where noted (designated NA for nonathlete) 
tAbbreviatlons: DHEA, Dehydroepiandrosterone; DHEAS, DHEA sulfate; A, Androstenedlone; T, Testosterone; 
PRL, Prolactin; TSH, Thyroid-stimulating hormone; T4, Thyroxine; Ej, Estrone; E2, Estradiol; 
NS, Statistically nonsignificant; MPW, Miles per week 
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conflicting results. Reduced basal concentrations of LH have been 
reported for araenorrheic runners (Baker, Mathur, Kirk, 5 Williamson, 
1981; McArthur et al., 1980), whereas similar concentrations have been 
reported by other investigators (Richards, Chang, Bossetti, Malarkey, 8 
Kim, 1985; Wakat et al., 1982). Schwartz et al. (1981) reported ele­
vated basal LH concentrations in amenorrheic runners as compared to 
eumenorrheic nonathletes during the early follicular phase of their 
menstrual cycle (g< .05). Differences in results may be attributable to 
the pulsatile nature of LH secretion. Analysis of a single sample has 
a predictable accuracy rate of only 38% (Santen 5 Bardin, 1973). 
The pulsatile pattern of LH release may be even more important 
than the mean LH concentration in regulating reproductive function 
(Loucks, 1985). Reduced frequency and amplitude of LH pulsations have 
been reported in amenorrheic runners (Veldhuis et al., 1985) and in 
eumenorrheic runners (Cumming, Vickovic, Wall, 6 Fluker, 1985). 
Veldhuis et al. (1984) demonstrated that in 6 normal men, venous 
sampling at 4-minute intervals disclosed 3.6-fold more LH pulses than 
could be detected with sampling intervals of 20 minutes. Thus, fre­
quent serial sampling is necessary to provide a comprehensive and 
accurate assessment of basal LH levels. Intervals of 20 minutes have 
been suggested as a minimum interval length for serial sampling in 
order to assess the secretory pattern of LH (Reame, Sauder, Kelch, 5 
Marshall, 1984). 
Follicle Stimulating Hormone. Basal FSH concentrations have con­
sistently been reported as similar to eumenorrheic athletes during the 
« 
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early-to-midfollicular phase (Richards et al., 1985; Schwartz et al., 
1981). Baker et al. (1981) reported no significant difference between 
the basal FSH levels of amenorrheic and eumenorrheic runners, but did 
not specify the cycle phase in which sampling occurred. 
Progesterone. Veldhuis et al. (1985) reported basal P values of 
both amenorrheic athletes and eumenorrheic nonathletes(early follicular 
phase) as less than 1.0 ng/ml. No other investigators have reported 
comparisons of amenorrheic vs. cyclic athletes or nonathletes. 
Shangold et al. (1979) observed lower midluteal phase plasma 
progesterone concentration during training (8.2+0.85 ng/ml) than during 
nontraining menstrual cycles (23.7+2.9 ng/ml) in 1 cyclic runner (£< 
.001). Dale, Gerlach, Martin, 6 Alexander (1979) also detected lower 
mean progesterone values among 19 runners than among 9 nonrunning ath­
letes and 13 sedentary controls, although the authors did not report 
the hormone values or level of statistical significance. Other 
investigators have reported lower plasma P levels associated with exer­
cise training (Bonen et al., 1981; Jacobson 5 Bonen, 1981; Jacobson et 
al., 1983). Ellison and Lager (1985) evaluated salivary P con­
centrations among cyclic runners who ran an average of 12.5 miles per 
week (MPW), and sedentary controls during the luteal phase. The 
runners' mean salivary P concentration was 194jK24 pmol/1, whereas the 
P concentration for the controls was 287+30 pmol/1 (£<.05). The 
authors concluded that even modest exercise is associated with a reduc­
tion in luteal phase P levels in the absence of obvious clinical evi­
dence of menstrual abnormality, and without excessive thinness. 
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Estrogen. Estradiol levels of 20.0+6.0 pg/ml among amenorrheic 
runners were significantly lower (g<.005) than the estradiol levels of 
eumenorrheic runners reported as 58.0_+8.0 pg/ml (cycle phase not spe­
cified) (Baker et al., 1981). Other comparisons between amenorrheic 
and menstruating runners have revealed no differences when controls are 
sampled during the early-to-midfollicular phase (Richards et al., 1985; 
Schwartz et al., 1981; Veldhuis et al., 1985). 
Schwartz et al. (1981) measured estrone in runners as well, and 
observed that the mean ratio of serum estrone to estradiol was signifi­
cantly higher (£<.01) among both amenorrheic and normally menstruating 
runners than among nonrunning controls. Gumming et al. (1981) observed 
a significantly higher level of estrone (]3<.01) among runners vs. 
untrained women in response to acute maximal exercise. 
Estradiol, the predominant and most active estrogen, normally 
constitutes about 95% of the total circulating estrogen (Yen, 1978). 
Under normal conditions, the estrone restradiol ratio is less than 1.0. 
An elevated ratio may be indicative of increased extraglandular 
conversion of androgens (peripheral androgen conversion is a signifi­
cant source of estrone); or the lack of ovarian follicle maturation, 
which results in diminished ovarian estradiol secretion (Yen, 1978). 
Accordingly, Schwartz et al. (1981) suggested that the runners' 
increased estrone : estradiol ratio observed was indicative of an 
alteration :in peripheral steroid metabolism, and that among the ame­
norrheic runners, the elevated ratios represented the absence of signi­
ficant ovarian follicular activity. Altered steroid metabolism among 
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the runners may be attributed to alterations in the rate of androstene-
dione production or clearance, or to abnormal conversion enzyme acti­
vity (Loucks 8 Horvath, 1985). 
Androgens. Elevated androgen levels may influence menstrual 
function through hypothalamic feedback or through a relative decrease 
in peripherally produced estrogen (Baker, 1981). Few researchers have 
evaluated androgen levels in female athletes. Dale, Gerlach, Martin, & 
Alexander (1979) observed higher serum testosterone levels among 19 
runners than among 22 nonrunners (exact values not reported), but the 
levels were still within the normal female range. In addition, the 
sampling protocol (i.e., resting or nonresting state) was not described. 
No significant differences in serum testosterone levels were reported 
between cyclic nonrunners, and amenorrheic and cyclic runners (Baker et 
al., 1981; McArthur et al., 1980; Richards et al., 1985; Schwartz et 
al., 1981; Veldhuis et al., 1985). 
In a prospective study of progressive exercise over several 
months, baseline testosterone levels did not increase with increasing 
distance run (Boyden, Pamenter, Stanforth, Rotkis, 6 Wilmore, 1983). 
Other androgens have been evaluated in a limited number of studies. 
No differences were observed between amenorrheic runners and eume-
norrheic runners in androstenedione, dehydroepiandrosterone (DHEA), or 
in DHEA sulfate (DHEAS) (Baker et al., 1981; Schwartz et al., 1981). 
On the basis of currently available data, there is little evidence of 
any abnormal androgen synthesis or clearance among amenorrheic 
athletes. 
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Prolactin. The physiological role for prolactin in follicular 
maturation and corpus luteum function is poorly understood; yet 
hyperprolactinemia is a recognized clinical syndrome associated with 
anovulation (Speroff et al., 1983, chap. 6). Both exercise and stress 
stimulate prolactin secretion (Reichlin, 1981, pp. 616-617). Normal 
basal prolactin concentrations have been reported for ballet dancers 
and runners with menstrual irregularities (Baker et al., 1981; Cohen et 
al., 1982; Richards et al., 1985). However, a progressive increase in 
the prolactin response to thyroid-stimulating releasing hormone (TRH) 
associated with increasingly weekly running mileage from 15 MPW to 64 
MPW has been observed (£<.04) (Boyden, Pamenter, Grosso, Stanforth, 
Rotkis 5 Wilmore, 1982). There was no correlation between TRH-
stimulated prolactin response and body composition. Hence, Boyden et 
al. concluded that exercise per se was probably responsible for the 
augmented prolactin response. The mechanism by which this would occur 
is unknown. Bullen et al. (1984) observed significant increases in 
prolactin levels in response to 60 minutes of graded exercise among 
healthy young women (JD<.05). The authors theorized that intermittent 
exercise-induced prolactin elevations could contribute to menstrual 
disorders, in light of the recognized association between hyperprolac­
tinemia and menstrual dysfunction. Bazzarre and Royster (1984) 
reported continued rises in prolactin among male marathon runners 
during a 2-hour submaximal (70% VO2 max) treadmill run, in contrast to 
growth hormone (GH), which peaked at 20 minutes and returned to base­
line levels thereafter. They postulated that exercise-induced release 
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of GH and prolactin are controlled by different hypothalamic regulatory 
mechanisms. Furthermore, they cited other reports in the literature 
that suggest that prolactin may function in the regulation of car­
bohydrate energy substrate availability during exercise stress. 
Perhaps an exercise-associated energy drain provides an additional 
stimulus for prolactin release due to increased need for glucose. 
Opioid Hormones. Endogenous opioids may function in the hypotha­
lamic regulation of LH secretion from the pituitary (Ellingboe, 
Veldhuis, Mendelson, Kuehnle, S Mello, 1982), and in the mechanisms 
governing several other pituitary hormones (Meites, 1980). 
Administration of naloxone, an opiate receptor antagonist, was reported 
to increase the amplitude of LH pulsations in hypothalamic amenorrheic 
women (Quigley, Sheehan, Casper, 6 Yen, 1980), and in 1 of 3 ame­
norrheic runners (McArthur et al., 1980). These findings suggest that 
endogenous opiates such as ^-endorphin, may diminish LH pulsatility. 
Some studies have demonstrated a rise in plasma y£-endorphin and in 
lipotropin in response to acute exercise, and that exercise training 
augments this response (Bullen et al., 1984; Carr et al., 1981). More 
research is required to quantify these exercise-induced changes. There 
is much concern, however, that peripheral opioid concentrations do not 
accurately reflect brain concentrations of the opioids. 
Evidence that both exercise and eating elevate /5-endorphins 
suggests that changes in energy substrate availability may alter the 
release of pituitary hormones. Walker, and Bazzarre (1985) cited a 
report in the literature (Givens, Wiedmann, Andersen, 8 Kitabchi, 1980) 
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noting elevated fasting -endorphins in obese, hirsute women with 
menstrual dysfunction. In their study, however, they observed no 
alterations in fasting ^-endorphin levels among obese females with 
no known menstrual dysfunction. Furthermore, in the study by Walker 
and Bazzarre, ^-endorphins decreased significantly following a 
12-week weight reduction program that emphasized physical activity 
and caloric restriction. 
Thyroid Hormones. Alterations in sex hormone metabolism have 
been documented in disorders of thyroid function (Fishman, Hellman, 
Zumoff, 5 Gallagher, 1962; Gordon, Southren, Tochimoto, Rand, 5 Olivo, 
1969), and are often associated with menstrual dysfunction (Burrow, 
1978). Normal thyroid function of oligo- and amenorrheic athletes has 
been demonstrated in most studies in which thyroid hormones have been 
evaluated (Cohen et al., 1982; McArthur et al., 1980; Veldhuis et al., 
1985; Wakat et al., 1982; Warren, 1980). However, Richards et al. 
(1985) reported significantly lower basal thyroxine (T4) levels among 
amenorrheic runners (7.3+1.2 mcg/dl) than sedentary controls (9.5+1.8 
mcg/dl) (jg<.05), whereas there was no significant difference in the T4 
levels of eumenorrheic runners (8.8+2.1 mcg/dl) and the controls. 
Schwartz et al. (1981) also observed evidence of thyroid dysfunction 
among amenorrheic runners. Basal levels of thyroid-stimulating hormone 
(TSH) were reduced among amenorrheic runners as compared to cyclic 
nonathletes or runners (exact values not reported; £<.05). 
Boyden, Pamenter, Stanforth, Rotkis, and Wilmore (1982) evalu­
ated thyroid function in women undergoing a prolonged endurance 
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training program. The investigators documented decreases in triiodothy 
ronine (T3) and reverse T3 (£<.03) as well as accentuated TSH response 
to TRH stimulation (£<.01). The underlying mechanism and the physiolo­
gical importance of this mild thyroidal impairment accompanying exer­
cise training is not known. The direct relevance to menstrual function 
remains unclear. In another report of the same study, Boyden et al. 
(1983) documented that amenorrhea did not develop in any of the 19 sub­
jects who completed the 14-month study. However, basal plasma estra­
diol concentrations decreased from 70.6+13.9 pg/ml at baseline to 33.6 
pg/ml (£=.03) following an increase in weekly mileage of 50 MPW. 
Gonadotropin Releasing Hormone. Administration of exogenous 
gonadotropin releasing hormone (GnRH) has produced normal or exag­
gerated LH responses among amenorrheic runners as compared to eume-
norrheic controls (McArthur et al., 1980; Veldhuis et al., 1985; 
Wakat et al., 1982). Such a response suggests that the pituitary is 
capable of synthesizing and storing LH, but that release of the gona­
dotropin is inhibited due to inadequate GnRH stimulation. Heightened 
sensitivity of the pituitary to exogenous GnRH may be indicative of a 
chronic low exposure to GnRH. 
Summary of Endocrine Review. Luteinizing hormone and FSH con­
centrations may be low or normal for early follicular phase values in 
the amenorrheic athlete, and LH is likely to exhibit a decreased pulse 
frequency. Luteal phase estrogen and progesterone may be reduced 
or within normal range. Androgen concentrations are in the normal 
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female range. Thyroid function may be normal or somewhat diminished as 
indicated by reduced levels of TSH. Basal prolactin levels can be 
expected to be normal. 
The ovaries and the pituitary of the amenorrheic athlete appear 
to be capable of normal function, although stimulation of the 
pituitary-ovarian axis may be impaired at the level of the hypothala­
mus. Evidence of pituitary hyperresponsiveness to exogenous GnRH 
suggests that hypothalamic GnRH release may be impaired. 
Further endocrine research is needed to gain an accurate repre­
sentation of the hormone profile that is characteristic of athletic 
amenorrhea. It is important to note as well, that circulating hormone 
concentrations cannot be directly equated with function. For example, 
changes in hormone turnover rates or in receptor sites or affinity may 
account for alterations in circulating hormone concentrations despite 
normal function of the hormone system. 
Proposed Mechanisms of Athletic Amenorrhea 
Early investigators of athletic amenorrhea attempted to gain some 
understanding of the etiology through cross-sectional studies designed 
to determine the usual characteristics of oligo- and amenorrheic 
athletes. Cause and effect cannot be ascertained from cross-sectional 
research, although exploratory data analysis of this nature has been 
useful in the development of hypotheses and experimental research 
designs. Many of the cross-sectional studies, as well as the few 
prospective studies that have been conducted, have provided conflicting 
results. Nevertheless, some consistent patterns have emerged, contri­
buting to the generation of hypotheses regarding mechanisms involved. 
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Factors such as physical or emotional stress, reproductive 
maturity, age of onset of exercise training, body composition, and diet 
have been suggested to be of etiological importance. For the purposes 
of this report, the discussion of proposed mechanisms will be limited 
to mechanisms associated with body composition and diet. 
Body Composition. Although widely publicized in the popular 
media, an association between low body weight or fat and menstrual 
disorders has not been consistently documented in the scientific 
literature. In 1974, Frisch and McArthur postulated that a critical 
weight for height, corresponding to a critical percentage of body fat, 
must be attained for the initiation of, as well as for the maintenance 
of, menstruation. Their conclusions have since been criticized for a 
number of reasons, including the statistical management of the data 
(Trussel, 1980) and methodology (Loucks, 1983). In addition, it is 
important to note that the amenorrheic subjects studied by Frisch and 
McArthur (n=17) were not athletes. The appropriateness of inferences 
to amenorrheic athletes from these data is, therefore, questionable. 
Several studies have failed to confirm a relationship between low 
body fat levels and the incidence of amenorrhea (Abraham et al., 1982; 
Calabrese et al., 1983; Feicht et al., 1978; Stager et al., 1984; 
Wakat, et al., 1982), further diminishing support for the theory that 
the reduction of body fat to some critical level causes the cessation 
of menses. Although a number of studies have revealed a greater ten­
dency toward amenorrhea among leaner athletes (Carlberg et al., 1983a, 
1983b; Dale, Gerlach, 5 Wilhite, 1979; Lutter 5 Cushman, 1982; Schwartz 
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et al., 1981), Frisch's hypothesis that a minimum level of body fat is 
required for normal menstrual function may be too simplistic. In most 
athletes, a low percentage of body fat is primarily a function of the 
energy expenditure associated with training. As pointed out by Bonen 
and Keizer (1984), amenorrhea cannot be attributed to leanness alone in 
an athletic population without also examining daily exercise, which is 
itself known to be a strong stimulant of the endocrine system. 
In her study of ballet dancers. Warren (1980) observed changes in 
menstrual function that occurred in relation to exercise levels, which 
were independent of body weight changes. Evidence of the effect of 
exercise on menstrual function (and on pubertal development) was 
stronger among the leaner dancers than among dancers with higher esti­
mated body fat. (Body fat was estimated from height and weight using 
the equation of Mellits and Cheek, 1970.) Sanborn et al. (1982), 
relying on retrospective survey data, reported that the prevalence of 
amenorrhea increased with weekly mileage among 237 runners, but no such 
relationship was observed among 197 swimmers or 33 cyclists. Noting 
that the runners reported lower weights for heights than the other ath­
letes, the investigators then categorized the runners into 3 weight 
groups, and found that the exercise-amenorrhea relationship was 
stronger in leaner runners. These results suggest an interplay between 
body fat and exercise levels as possibly being an important etiological 
factor. 
Loss of body weight has been associated with menstrual dysfunc­
tion among nonathletes (Graham, Grimes, S Gambrell, 1979; Knuth, Hull, 
8 Jacobs, 1977). This relationship has also been documented for 
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athletes (Bullen et al., 1985; Lutter 5 Cushman, 1982; Speroff 5 Redwine, 
1980). Few investigations have addressed the issue specifically, 
though, and a causal relationship has not yet been demonstrated. 
In a study of 24 amenorrheic women, Wentz (1980) concluded that 
the loss of fat is more important than absolute body weight in the 
etiology of amenorrhea. In contrast to the theory that absolute weight 
is a determinant of menstrual function, she noted that a wide range of 
body weights was associated with the onset of amenorrhea. All of the 
amenorrheic women except for 3 runners, however, had lost a substantial 
amount of weight. Wentz speculated that the runners' body composition 
had changed with the training despite no apparent weight changes. She 
has insisted that weight measurements alone are insufficient to assess 
the effect of fat loss on menstrual function. Decreasing levels of 
body fat with no change in weight have occurred in women participating 
in an endurance running program (Boyden, Pamenter, Stanforth, et al., 
1982). Wentz maintains that a shift in body composition from fat 
toward muscle, with or without weight loss, may affect gonadal hormone 
production. 
Adipose tissue serves as a site for the aromatization of androgen 
precursors to estrogens (Speroff et al., 1983, chap. 1). The loss of 
body fat may reduce a significant amount of available tissue for extra-
gonadal estrogen production, thereby altering estrogen feedback 
influences on GnRH (Rebar 5 Cumming, 1981; Wentz, 1980). Steroid con­
versions also occur in muscle tissue (Longcope, Pratt, Schneider, 6 
Fineberg, 1978). Refuting the theory that body fat levels are critical 
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to menstrual function, Bonen and Keizer (1984) proposed that increased 
muscle mass may represent a compensatory source of estrogen in very 
lean athletes. 
There is evidence that estrogen metabolic pathways vary according 
to body weight and fat levels. Fishman, Boyar, and Hellman (1975) com­
pared urinary metabolites of labeled estrogen between 7 women with 
anorexia nervosa, 4 obese women (75% over normal body weight), and 8 
controls. In the obese women compared to the anorectic women, there 
was a greater formation of the estrogen metabolic byproduct estriol 
(jK.Ol), suggesting greater estrogen synthesis and breakdown. Urinary 
levels of the catecholestrogen 2-hydroxyestrone were markedly increased 
if 
in the anorectic women (£<.01), and decreased in the obese (£<.02), as 
compared to controls. The estrogenic activity of 2-hydroxyestrone 
is only about 0.01% that of estradiol (Gordon et al., 1964), and may 
actually function as an antiestrogen due to its greater affinity for 
uterine cytosol receptors (Martucci 5 Fishman, 1976). It is tempting 
to infer from the endocrine conditions associated with obesity and with 
anorexia nervosa that an increasing estrogenicity is associated with 
increased body fat. Fishman (1980) has pointed out, however, that the 
increased peripheral aromatization observed in obese women does not 
decrease with weight loss. Furthermore, there has been no documen­
tation of a reversal of the 2-hydroxylation deficit among obese women 
in response to weight loss. 
Diet. Few studies of athletic amenorrhea have included dietary 
assessment. A number of hypotheses related to dietary factors have 
been proposed, however. 
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The results of two studies have suggested a possible association 
between hypercarotenemia and menstrual dysfunction (Page, 1971; Kemman, 
Pasquale, 5 Skaf, 1983). Ten anovulatory women with elevated serum 
carotene levels were studied by Kemman et al. There was no evidence of 
hyperprolactinemia or thyroid dysfunction among the subjects. Diets of 
all of the women were characterized by a high intake of raw vegetables 
and a lack of red meat. These patients were counseled to reduce their 
intake of carotene-rich foods and to increase their protein consumption. 
In the 2 patients who did not alter their diets, elevated serum caro­
tene levels as well as amenorrhea persisted. The other patients 
menstruated subsequent to diet modification and a reduction of serum 
carotene levels. 
In the study by Kemman et al. (1983), dietary assessments were 
based on interviews. The authors failed to evaluate (or to report) 
relevant dietary information such as energy or protein intake. Nor 
was there any indication that other lifestyle factors were investigated 
following the completion of initial interviews and questionnaires. 
Information regarding stress and exercise levels, for example, would be 
useful. In addition, it is important to note that one patient was a 
professional ballet dancer, and that one patient had lost more than 4.5 
kg of body weight prior to the onset of her menstrual dysfunction. In 
these two women, therefore, exercise or weight loss may have contri­
buted to the onset of amenorrhea. 
Frumar, Meldrum, 6 Judd (1979) reported that carotenemia was 
present in 6 patients with hypogonadotropic amenorrhea, which was 
not associated with an excessive intake of carotene-rich foods. 
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Frumar et al. proposed that the hypercaroteneraia was attributable to 
weight-induced catabolic changes including lipid mobilization. It has 
been suggested that carotene exerts a peripheral antiestrogenic effect 
(Romney et al., 1981, p. 894), but there is little evidence to support 
this contention. 
Richards et al. (1985) evaluated serum carotene levels of 7 eume-
norrheic and 8 anovulatory runners, and 5 sedentary controls. Serum 
carotene levels were similar in the three groups, and only 1 ame-
norrheic runner exhibited a serum carotene level above the upper limit 
of normal (274 mcg/dl vs. 250 mcg/dl). The authors concluded that 
hypercarotenemia is not associated with menstrual dysfunction among 
long-distance runners. 
One nutritional challenge for the endurance athlete is to main­
tain an energy intake that is sufficient to compensate for high energy 
demands. Reflecting this high energy expenditure, the mean percentage 
of body fat among competitive female distance runners has been reported 
to be approximately 15% (Butts, 1982; Wilmore 5 Brown, 1974), and as 
low as 8-10% among nationally ranked women runners (Costill, 1979, p. 
11). This is well below the normal value for nonathletic adult fema­
les, which has been estimated to be approximately 25% (Durnin 6 
Rahaman, 1967; Wilmore 5 Behnke, 1970). 
Warren (1983) has proposed that while amenorrheic athletes do not 
appear to be malnourished, the energy drain they experience may 
resemble that of undernutrition as seen in anorexia, a syndrome in 
which the incidence of amenorrhea is high. Thus, she purports that a 
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caloric deficiency may exist relative to the energy demands of physical 
training. 
Among adolescent ballet dancers, progression of sexual develop­
ment and the onset of menstruation was associated with forced exercise 
cessation of at least 2 months (Warren, 1980). In the same study, 11 
out of the 13 dancers became amenorrheic again upon resumption of 
exercise. Several studies have provided evidence of a positive asso­
ciation between exercise levels and the incidence of menstrual irregu­
larities (Abraham et al., 1982; Bullen et al.f 1985; Carlberg et a!., 
1983b; Lutter 8 Cushman, 1982). In a number of surveys, athletes have 
reported a perceived association between their exercise level and 
menstrual patterns (Calabrese et al., 1983; Dale, Gerlach, Martin, 8 
Alexander, 1979; Schwartz et al., 1981; Wakat et al., 1982; Webb 5 
Proctor, 1983). 
Warren has suggested that the amenorrhea associated with exercise 
or with weight loss may represent a physiological adaptation to large 
metabolic demands, and that it may serve as a natural form of fertility 
control. She cites evidence of such a phenomenon among females of the 
IKung bushmen of South Africa, who have exhibited low plasma estradiol, 
progesterone, and testosterone levels, suggestive of suppression of 
ovulation (van der Walt, Wilmsen, 6 Jenkins, 1978). Van der Walt et 
al. believed that the caloric-deficient diets of the IKung women during 
the hot dry season may be associated with the apparent ovarian 
suppression. The birth rate of the IKung peaks at exactly 9 months 
from the time of the year when their body weight is at maximum. Van 
der Walt et al. hypothesize that a mechanism exists whereby ovarian 
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suppression in response to undernutrition serves to limit conception 
to times of high nutrition. 
Winterer, Cutler, and Loriaux (1984) support the theory that 
menstrual function is affected by caloric balance. They propose that 
when caloric availability is reduced beyond a critical level, GnRH 
release is impaired. Winterer et al. suggest that energy drain may 
contribute to delayed menarche as well as to secondary amenorrhea. 
Although few investigators of athletic amenorrhea have assessed 
energy intake, none have evaluated energy balance. The amenorrheic 
runners studied by Schwartz et al. (1981) consumed 1800 kcal per day, 
yet were running about 40 miles per week, as well as participating in 
other routine exercises. The oligo- and amenorrheic dancers studied by 
Calabrese et al. (1983) reported an even lower mean caloric intake. 
The dancers' intake of 1360 kcal/day is 71.6% of the U.S. Recommended 
Dietary Allowance (RDA) (National Research Council, 1980). The inves­
tigators speculated that progressive weight loss did not occur in the 
dancers because of the high incidence of food binging (70%) reported. 
It is also possible, however, that a physiological adaptation to a low 
energy intake results in increased metabolic efficiency, i.e., a 
reduced basal metabolic rate (Sukhatme 6 Margen, 1982). 
In contrast to the energy drain theory, the caloric intake of 
amenorrheic runners (1730HHB3 kcal/day was similar to that of eume-
norrheic runners (1795^140 kcal/day) (Berning, Sanborn, Brooks, 6 
Wagner, 1985). All of the subjects ran more than 40 miles per week and 
participated in other vigorous athletic activities. Although the 
runners' actual energy expenditure was not quantified, the authors 
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noted that the mean intake of the runners did not appear to be adequate 
to maintain such a level of energy expenditure. Comprehensive dietary 
analysis together with reliable estimates of energy expenditure are 
needed to address the relevance of energy drain to the development of 
menstrual dysfunction. 
The dancers studied by Calabrese et al. (1983) reported a mean 
protein consumption that met 99% of the RDA (National Research Council, 
1980). However, their mean protein intake of 47.4 g/day may be inade­
quate as a consequence of their deficient energy intake (1360 kcal/day) 
(Inoue, Yoshiaki, 5 Yoshiaki, 1973). The amenorrheic runners studied 
by Schwartz et al. (1981) consumed a lower percentage of kcal as pro­
tein than cyclic runners or nonathletic controls (£<.01). In light of 
the runners' weekly mileage (40 MPW) and other exercise activities, a 
daily energy intake of 1800 kcal would appear to be insufficient to 
support energy demands. The adequacy of the energy intake (and there­
fore, of protein) was not addressed by the authors, however. 
Lean body mass serves as an energy source during periods of 
caloric insufficiency (Van Itallie Q Yang, 1978). Moreover, there is 
increasing evidence that protein may contribute significantly to energy 
metabolism during exercise (Evans, Fisher, Hoerr, 5 Young, 1983), and 
that aerobic exercise training may increase protein requirements 
(Hoerr, Young, 6 Evans, 1982). Amino acid deficiency (primary, or 
secondary to energy insufficiency) may lead to impaired neurotrans­
mitter synthesis (Fernstrom, 1981), which may affect LH release from 
pituitary cells as well as GnRH release from the hypothalamus (Wentz, 
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Jones, 5 Sapp, 1976). Unfortunately, no studies have investigated pro­
tein balance among amenorrheic athletes. 
Goldin et al. (1982) evaluated the dietary intake and estrogen 
status of 10 vegetarian and 10 nonvegetarian women. The vegetarians, 
who had a greater fecal weight (£=.005), also had a greater fecal 
estrogen excretion (£<.03) than the omniverous women. Among the 
vegetarians, plasma estrone and estradiol were negatively correlated 
with fecal estrogen excretion (£=.005). 
The high fiber content of the vegetarian diet (28 g/day vs. 12 
g/day in the omniverous diet), leading to a greater fecal bulk, may be 
responsible for the increased fecal excretion of estrogen and a con­
comitant decrease in plasma estrogens. Goldin et al. (1982) offer an 
alternative hypothesis, however, based on the observation of reduced 
activity of -glucuronidase activity in the feces of the vegetarians 
(£<.05). -glucuronidase is an intestinal enzyme that is responsible 
for deconjugating biliary estrogen conjugates, which is necessary for 
estrogen reabsorption. Thus, it appears that some factor of the vege­
tarian diet reduced ^-glucuronidase activity, thereby contributing to 
increased estrogen excretion. 
Dietary fiber has been associated with a reduction of -
glucuronidase activity, and dietary fat and beef have been associated 
with increased activity of the enzyme in rats (Goldin 6 Gorbach, 1976). 
It is not possible to determine from the study by Goldin et al. (1982) 
which dietary factor is responsible for the elevated estrogen 
excretion. In addition to their greater fiber consumption (£<.001), 
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the vegetarians also consumed less fat than the omnivores (34 g/1000 
kcal vs. 44 g/1000 kcal; £<.05). 
Howie and Schultz (1985) investigated the diets and plasma hor­
mone levels of male vegetarian Seventh-Day Adventists (SDA), non-
vegetarian SDA, and non-SDA nonvegetarians. Vegetarian SDA consumed 
significantly more crude and dietary fiber than did nonvegetarian SDA 
(£<.05) and non-SDA nonvegetarians (£<.025). The vegetarians also 
exhibited a lower plasma testosterone level (£<.02) and estradiol-17/S 
level (£<.05) than non-SDA nonvegetarians. Dietary intake of total fat 
and fat/1000 kcal was similar between the three groups. Regression 
analysis revealed a statistically significant inverse relationship 
between plasma estradiol-17/S level and crude fiber intake among the 
subjects (£<.001). 
Brooks, Sanborn, Albrecht, and Wagner (1984) analyzed the diets 
of 15 amenorrheic and 15 eumenorrheic runners who were similar in age, 
menarcheal age, exercise level, and percentage of body fat. They 
reported that 82% of the amenorrheic runners were vegetarians, whereas 
only 13% of the cyclic runners were vegetarians. Protein, energy, and 
fiber intakes were similar between the two groups. Fat consumption was 
the only dietary variable that differed significantly; the eumenorrheic 
runners consumed a mean of 98 g of fat per day, and the mean intake of 
the amenorrheic runners was 68 g/day (£<.05). The investigators 
suggested that a lower intake of certain minerals such as zinc or iron, 
which may accompany a vegetarian diet, may be of etiological importance. 
The low fat content of a vegetarian diet may affect the availability of 
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hormonal precursors as well, especially in combination with a negative 
energy balance. 
Based on the review of the literature, the following points have 
been established. 
1. Menstrual irregularities appear to be more prevalent among 
leaner athletes, although several reports have indicated no difference 
in the body composition of eumenorrheic and amenorrheic athletes. 
2. The caloric intake of some amenorrheic athletes appears to be 
insufficient to meet predicted energy demands of their training. 
3. A number of amenorrheic athletes consume vegetarian diets. 
4. No prospective exercise studies have included a comprehensive 
dietary component. 
The present investigation was designed in an attempt to answer 
some of the dietary questions related to athletic amenorrhea. 
Specifically addressed was the question of whether a negative protein 
and/or energy balance is related to the development of exercise-
associated menstrual irregularities. 
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CHAPTER III 
METHODS 
Subjects 
Twenty-one apparently eumenorrheic recreational runners, ages 
18-40, were recruited for the study. Recruitment fliers (Appendix A) 
were distri buted in the monthly newsletter of a local running club, 
and at running races in the Greensboro, NC area. Newspaper and radio 
public service announcements were also utilized, as were notices 
posted at the University of North Carolina at Greensboro (UNCG), local 
colleges, health food stores, sporting goods stores, and fitness cen­
ters in Greensboro. 
At recruitment, subjects ran 10-25 miles per week. They con­
sumed no steroid drugs or unusual diets for at least 6 months prior to 
study participation. Volunteers were screened from participation for 
any of the following reasons: history of metabolic or pituitary 
disorders, hypertension, more than 10% under or 20% overweight for 
height, and regular use of tobacco or marijuana. 
The study was approved by the Human Subjects Review Committee of 
UNCG. Before signing a consent form (Appendix B), subjects were fully 
informed of the study procedures. The potential risks and benefits of 
the project were described to all participants. 
Questionnaires regarding personal and medical histories were 
completed by the subjects at the beginning of the study (Appendix 
C). The prestudy questionnaire included questions regarding athletic 
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history; menstrual history; tobacco, drug, and alcohol use; diet; and 
changes in body weight since beginning running. 
Each subject selected the group in which she would participate; 
experimental (E) or control (C). Control subjects each maintained a 
running program that was relatively consistent with their pre study 
training (i.e., the weekly distance run and the intensity of the 
workouts were held constant). The E group received coaching that was 
designed to increase running mileage and speed as tolerated by the 
subjects. The coaching was provided by an experienced competitive 
runner (J. C. S.). Two high-intensity workouts per week were usually 
included in the training schedules. The high-intensity workouts 
(speed-training) included an anaerobic component, and were sometimes 
performed at the track. Most subjects had no previous exposure to 
this type of training. 
Experimental Design 
For the entire study period, which spanned 7 menstrual cycles, 
running was the only significant source of physical activity for the 
subjects. All runners kept an exercise log, which was reviewed regu­
larly by the E group coach and project coordinator, as a means of 
monitoring study and coaching compliance. 
Subjects from both groups consumed a lacto-ovo vegetarian diet 
for the duration of the study because the measurement of urinary 
3-methylhistidine requires a flesh-free diet. Information on how 
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to plan a well-balanced vegetarian diet was provided to subjects, who 
were encouraged to contact any of the project investigators if there 
were specific questions or concerns about the diet. 
During the experimental period there were 19 workshops held that 
were designed to educate subjects about running, diet, and other 
aspects of health. In addition, the workshops provided a vehicle for 
communication to and between subjects. The workshops were designed to 
motivate subjects to comply with the study protocol. Lacto-ovo vege­
tarian meals along with printed recipes were offered as healthy 
examples of this meal pattern. 
The study consisted of four data collection periods designated 
as Test Periods I through IV (TP I-IV), corresponding to the 1st, 3rd, 
5th, and 7th menstrual cycles of each subject. During each test 
period, which began on Day 3 of each subject's menstrual cycle (Day 
1 = onset of bleeding), the following data were collected: a 7-day 
diet record, a 7-day activity record, seven 24-hour urine samples, 
body weight, and body fat estimations by hydrostatic weighing and 
skinfold measurements. Height was measured at TP I. 
From the tenth day of each subject's menstrual cycle until the 
next onset of menstruation, blood samples were obtained every other 
day during TP I and IV only. Maximal oxygen uptake and resting meta­
bolic rate were also measured during the first and last test periods. 
A data-collection summary appears in Table 2. 
Table 2 
Data collection 
Test period 
Prestudy 
(Baseline; first 
menstrual cycle) 
I-A 
II and III 
(Third and 
fifth menstrual 
cycle) 
IV 
(Seventh 
menstrual 
cycle) 
IV-A 
Tests and data collection 
Personal, medical, athletic, and menstrual 
histories 
3-day food record3 
Two 7-ml fasting blood samples3 
Height, weight, skinfold thicknesses,b 
and hydrostatic weight 
Resting metabolic rate 
Maximal oxygen uptake 
For each of Days 3-10 of menstrual cycle:0 
24-hour food record, 24-hour activity record, 
and 24-hour urine collection 
From Day 10 of menstrual cycle until the onset 
of the next cycle: Two 10-ml blood samples, 
every other day 
Weight, skinfold thicknesses,*3 hydrostatic 
weight 
24-hour food record, 24-hour activity record, 
and 24-hour urine collection (Days 3-10 of 
cycle) 
Two 7-ml fasting blood samples (Day 10 of cycle) 
Identical to Test Period I, but with following 
differences: 
Height measurement omitted 
Two 7-ml fasting blood samples (Day 10 of cycle) 
See Test Period I-A 
aData collected for separate study 
^Skinfold thicknesses measured at 4 sites 
scapular, and suprailiac 
cDay 1 = first day of menstruation 
biceps , triceps , sub-
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Collection of Dietary Data 
Subjects were given detailed instructions on how to keep a daily 
food record in household measures (Appendix D), and were encouraged 
to include product labels and recipes for unusual foods in their 
food records. The subjects collected a 7-day food record at each test 
;i 
period. Nutrient intakes were calculated using the Nutranal nutri­
tional analysis program (S.N. Services, Denver, CO). Analyses of the 
records included the following: kilocalories (kcal); protein, car­
bohydrate, fat, absolute quantities and percentage of kcal; saturated 
and polyunsaturated fatty acids; cholesterol; dietary fiber; iron; and 
zinc. Protein intake was also determined as g protein per kg of body 
weight, and per 1000 kcal. 
Activity Records and Running Mileage 
Activity records (Appendix E) were completed for 7 days of each 
test period according to the method of Bouchard et al. (1983). For 
recording purposes, each day was divided into ninety-six 15-minute 
intervals. Subjects entered a number ranging from 1-9 for each 
15-minute period, corresponding to the predominant level of physical 
activity for that time period. The nine activity categories were 
explained to the subjects, and they were given written guidelines. 
Energy expenditure was calculated using the estimated energy costs of 
the Physical Activity Levels 1-9 developed by Bouchard et al. 
All subjects were given a running logbook (Appendix F) in which 
they recorded for each workout, the date, the number of miles run, 
total running time, and exercise heart rates when measured. 
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Additional space was provided to record any other relevant information 
about the workout, i.e., how the run felt that day, any pain or injury 
problems, weather conditions, or shoes worn. 
The usual weekly mileage (MPW) recorded for each subject at TP I 
was ascertained by prestudy interview, and confirmed by questionnaire 
upon entry to the study. Values for weekly running mileage for sub­
sequent test periods represent the average weekly mileage of the pre­
ceding four weeks, as recorded in the subjects' logbooks. 
Anthropometric Measurements 
Each test period included measurements of weight (in kg), 
hydrostatic weight, and skinfold thicknesses. Height and weight were 
measured with a beam balance scale with an attached stadiometer. 
Hydrostatic weighing was performed according to the procedure of 
Sinning (1975, chap. 7). Body density and fat was estimated using the 
equation of Brozek, Grande, Anderson, and Keys (1963). Residual lung 
volume used in the body density equation was estimated (Wilmore, 1969). 
Skinfold thicknesses, measured on the right side of the body, 
included the following sites: biceps, triceps, suprailiac, and 
subscapular. All measurements were performed using a Lange skinfold 
caliper by the same individual to eliminate inter-examiner variation. 
The sum of skinfolds was used to estimate body fat according to the 
equation developed by Durnin and Womersly (1974). 
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Measurement of Work Capacity and Resting Metabolic Rate 
Maximal oxygen consumption (VO2 max) was measured at pre- and 
poststudy. Subjects performed a maximal exercise stress test 
following the Bruce protocol (Bruce, Kusumi, and Hosmer, 1973). 
Expired air samples were analyzed with Beckman O2 and CO2 analyzers 
calibrated with gases of known concentrations. Attainment of VO2 max 
was determined on the basis of the following criteria: treadmill 
duration, heart rate, respiratory exchange ratio, and leveling off of 
V02« Measurements of VO2 max were intended to confirm that (a) E sub­
jects had complied with the exercise program, and (b) C subjects had 
not increased the quantity or quality of their training. 
Resting metabolic rate (RMR) was assessed pre- and poststudy in 
an effort to detect physiological adaptation to an energy deficit 
should it occur in any of the subjects. Subjects reported to the UNCG 
Human Performance Laboratory immediately after arising in the morning 
in a 12-hour postabsorptive state. They then rested in a reclining 
position for 20-30 min, after which 5-min breath samples were 
collected for RMR estimation via indirect calorimetry (McArdle, Katch, 
and Katch, 1981, chap. 9). 
Urine Samples 
Twenty-four-hour urine samples collected for each entire 7-day 
test period were begun following the first void of the first day of 
the test period and included the first void of the next day. Samples 
were collected in containers into which 10 ml of N HC1 had previously 
been added. Following each 24-hour period subjects measured 
42 
and recorded total urine volume using either 500- or 1000-ml graduated 
cylinders. A 100-ml aliquot was then frozen. At the end of each test 
period, the seven frozen samples were brought to the laboratory where 
they were stored at -20°C until preparation for hormone assay and 
3-methylhistidine determination. 
Determination of Urinary 3-Methylhistidine and Creatinine 
Urinary 3-methylhistidine (3-MH) was measured according to the 
high-pressure liquid chromatography method of Wassner, Schlitzer, and 
Li (1980), which involves sample deproteinization and precolumn 
derivatization. Sodium borate was added to the deproteinized samples 
to increase the pH to approximately 12, which is necessary for the 
formation of fluorescamine derivatives. An acetonitrile-fluorescamine 
solution was then added, after which the sample pH was reduced to 
about 2 with concentrated perchloric acid, and samples were heated in 
a water bath at 70°C for one hour. Before loading on the column, 
samples were neutralized with 0.5 morpholinopropanesulfonic acid in 3 
M NaOH. 
Only two of the 24-hour urine samples per subject per test 
period were analyzed for 3-MH. In an effort to control for the poten­
tial effects of exercise on 3-MH excretion (Dohm, Williams, Kasperek, 
8 van Rij, 1982), samples to be analyzed were chosen from a day 
following an exercise day and from a day following a nonrunning day. 
Wilcoxon signed-ranks tests of the difference between the exercise-
and the nonexercise-day excretion of 3-MH revealed no significant 
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differences between the two samples. The two 3-MH values from each 
test period were then averaged to represent the respective test period 
values. 
Urinary creatinine was determined by the Jaffe reaction (1886) 
as modified by Chasson, Grady, and Stanley (1961), utilizing the 
Technicon Autoanalyzer 11™. This method is based on the reaction of 
saturated picric acid with creatinine in the presence of alkali. 
Determination of Urinary Luteinizing Hormone 
Urine samples were prepared for luteinizing hormone (LH) assay 
in the following way. Frozen aliquots of urine were thawed and 
centrifuged, and the pH adjusted to 4.5 with concentrated HC1. To 15 
ml of urine, 4 drops of 30% bovine serum albumin and 30 ml of acetone 
were added. Samples were then vortexed and placed in the freezer at 
approximately -20°C for 30 to 45 minutes. Subsequent centrifugation 
yielded a pellet which was then lyophilized to dryness and stored at 
room temperature until assays were performed. 
Reagents were supplied by the hormone distribution program of 
the National Institute of Arthritis, Diabetes, and Digestive and 
Kidney Diseases (NIADDK) (Bethesda, MD). The LH concentrations were 
measured in the laboratory of Alan D. Rogol, M.D., Ph.D., Departments 
of Pediatrics and Pharmacology, University of Virginia (UVA) School of 
Medicine (Charlottesville, VA). The double antibody radioimmunoassay 
(RIA) used for the measurement of urinary LH was a modification of the 
technique of Odell, Ross, and Rayford (1966). All samples were run in 
duplicate, and at two different dilutions. Urinary extract, first 
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antibody, and 125i_i0Ci0_LH were incubated for 3 days at 4°C. The 
antibody-bound iodo-LH was then precipitated with second antibody. 
The precipitate was collected by centrifugation and the supernatant 
solution was aspirated. The remaining pellets were counted for gamma 
radiation. 
Collection of Blood Samples 
Most blood samples were drawn by coinvestigators of the project, 
with alternative blood-drawing arrangements made when necessitated by 
subjects' travel or proximity to the university. Peripheral venous 
samples to be used for plasma progesterone analyses were collected in 
Vacutainers'" containing EDTA (Fisher Scientific, Raleigh, NO, while 
samples for serum luteinizing hormone analysis were collected in 
Vacutainers™ with no anticoagulant. 
Blood was centrifuged at 2500 rpm for 15-20 min, after anti­
coagulant-free Vacutainers™ had remained at room temperature 30-90 min 
to allow clotting. Plasma or serum was then decanted and samples were 
frozen at -20°C. Frozen samples were packed in dry ice and transported 
to the University of Virginia (Pediatric Endocrinology, UVA School of 
Medicine, Charlottesville, VA) where they were stored frozen until 
hormone analyses were performed. 
Determination of Serum Leutinizing Hormone 
and Plasma Progesterone 
Duplicate samples of serum LH were measured using the 
modified method of Odell et al., (1966), as previously described. 
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Measurements of plasma progesterone (P) were also carried out in 
duplicate, employing the technique of Thorneycroft and Stone (1972). 
All LH assays were performed in the laboratory of Dr. A. Rogol, and P 
was measured in the laboratory of Johannes D. Veldhuis, M.D., 
Department of Internal Medicine, UVA School of Medicine. 
Interpretation of Hormone Data 
FiVe distinct variables were derived from the hormone data. 
These variables are (a) the number of days between the LH peak and the 
P peak; (b) the number of days in the test period in which the 
subject's plasma P concentration was 6.0 ng/ml or greater; (c) the 
number of days plasma P concentration was 4.0 to 5.9 ng/ml; (d) the 
number of days plasma P concentration was less than 4.0 ng/ml; (e) the 
area under the curve for P vs. time. 
Each subject's hormone concentrations were plotted against time, 
serum LH aiid plasma P both occupying the same graph (Appendix G). 
The number of days between the LH surge and P peak was counted as 
evidence of the length of the luteal phase. For three subjects these 
TP I values were unavailable, due to a nondetectable P peak (Subjects 
3 and 23) or to missing data (Subject 8). 
The classifications of P concentration were chosen to represent 
three ranges indicative of luteal adequacy (6.0 ng/ml or greater), 
inadequate luteal phase (< 4.0 ng/ml), and a midrange (4.0 - 5.9 
ng/ml) (A. D. Rogol, personal communication, October 8, 1985). The 
area under the P-vs .-time-curve was determined by summation of the P 
concentrations for Days 10 through the end of the subject's cycle. 
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Since blood was drawn only every other day during test period 
cycles, and because of the difficulties in coordinating blood-drawing 
with subjects1 schedules, actual measured values of hormone con­
centrations are not available for all days in the test period. When a 
scheduled blood-drawing was missed, subjects came for blood-drawing on 
the following day, whenever possible. All missing blood samples were 
handled in the following ways: 
1. Hormone concentrations of a nonblood-drawing day falling 
between two days on which blood sampling occurred were estimated to be 
the average value between the days preceding and following that day. 
For example, if the P concentration was determined to be 0.9 ng/ml on 
Day 16, and 3.1 ng/ml on Day 18 of a subject's cycle, then Day-17 P 
concentration would be estimated to be 2.0 ng/ml. In the event that 
two consecutive days of samples were missing, an estimate for each day 
was obtained from the graph of the plotted known values. 
2. If a blood sample was missing at Day 10 or at the end of a 
test period, then the 10th day or last day of the cycle was presumed 
to correspond with what appeared to be "baseline" concentrations for 
P. Estimated concentrations of missing values directly following Day 
10 or immediately preceding the last day of the cycle were based on 
the averages falling between known concentrations and the presumed 
"baseline" values. (Blood samples for some subjects were drawn on 
Day 1 of the cycle following the test period. In these cases, the 
nontest period-progesterone value was used to estimate the P 
concentration of the last day of the test period.) The following are 
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subjects for whom blood samples are unavailable for the beginning or 
end of the scheduled blood-drawing days for a given test period. Raw 
hormone data for each subject, indicating actual values measured and 
those estimated, as well as graphic displays of the data are presented 
in Appendix G. 
Days of Cycle for which Blood 
Subject Samples are Missing 
02 10, TP I 
03 29-33, TP I 
04 25-28, TP I 
06 29-30, TP IV 
08 28-36, TP I 
09 33-34, TP I 
11 10-12, TP I; 26-28, TP IV 
15 25-26, TP I 
21 10, 24-26, TP I 
22 10, TP I 
In summary, there were one or more missing blood samples for 
nine of the subjects at Test Period I. At Test Period IV, there 
were 2 and 3 missing blood samples for two subjects, respectively. 
Workshops 
Workshops were conducted weekly at the beginning of the study, 
and approximately semiweekly by the end of the study. Project coin-
vestigators and guest speakers addressed a variety of topics, i.e., 
vegetarianism, nutrition and exercise performance, race strategies, 
stretching, injury prevention, body composition evaluation, and 
safety. One coinvestigator prepared vegetarian meals at each work­
shop, and provided printed recipes of all foods prepared. A brief 
discussion of the meal was included at each session for clarification 
of food preparation and of the nutritional contribution of each item. 
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A UNCG women runners' club was established in conjunction with 
the study, on the basis of a perceived demand for an organization that 
could provide camaraderie, information, and support to local women 
runners. The investigators believed that nonsubjects could be helpful 
to study participants in terms of motivation and compliance. 
Membership for nonsubjects included coaching (individualized training 
schedules) from the project coordinator/coach in addition to the regu­
larly scheduled workshops, which served as club meetings for the group 
that became known as the "Women Runners Research Club." Membership 
fees from nonsubjects financed the meals provided at the workshops. 
Statistical Analyses 
All of the statistical analyses were performed using the SAS 
statistical computer package. Variables were evaluated for compliance 
with the assumptions required of subsequent statistical tests. 
Nonparametric analyses were employed because of the distributional 
characteristics (nonnormal, limited ranges) of the variables and small 
sample size. 
In order to evaluate the magnitude of change from TP I to TP IV 
for each group, variables representing change over time were created. 
The Wilcoxon signed-ranks test was used to assess the magnitude of 
change within C and E. If the null hypothesis (no change) is true, 
then the probability of observing a positive difference of a given 
magnitude is equal to the probability of observing a negative dif­
ference of the same magnitude. Sufficiently small values for the sums 
of the signed ranks (positive or negative, separately), therefore, 
justifies rejection of the null hypothesis. 
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To test differences between C and E, as opposed to within each 
group, the Wilcoxon two-sample test was used. This analysis is simi­
lar to the signed-ranks test, requiring ranking of the data for sub­
sequent analysis. Observations from each group are combined and 
ranked from the smallest to the largest value. The sums of the ranks 
for each population are then compared. One assumes that the sums will 
be close in value if the two population distributions are similar. 
For all variables, the median is reported in lieu of the mean. 
The median is a better representation of the population's central ten­
dencies due to skewness of many of the variable distributions. In 
addition, reporting median values is consistent with the use of the 
median in the signed-ranks test. 
In addition to the previously described procedures, the Day 10 
blood samples from each test period were analyzed for hemoglobin, 
hematocrit, serum ferritin, serum cholesterol, and plasma zinc. These 
assays were carried out for separate reports of the present study, 
although the results of the measurements are included in the present 
report for descriptive purposes. Hematocrit values were obtained via 
microcentrifugation. Hemoglobin was analyzed using the cyanmethomo-
globin method (Interdepartmental Committee on Nutrition for National 
Defense, 1963). Serum ferritin was measured using a solid-phase 
enzyme immunoassay kit from Abbot Laboratories (North Chicago, IL). 
A description of serum cholesterol and plasma zinc assays are pre­
sented in Appendix H. 
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CHAPTER IV 
RESULTS 
Nineteen of the 22 original subjects completed the study; one 
subject moved away from the area, and two subjects found the study to 
be incompatible with their lifestyles at that time. The data from one 
E subject were judged to be unreliable by the investigators, and have, 
therefore, been excluded from all analyses. The data of one C subject 
were also omitted because of the subject's lack of compliance to the 
study protocol. Finally, the TP IV endocrine data from one C subject 
have been omitted from analysis because she became pregnant in the 
last test period. Other data from this subject are included in sta­
tistical anaylses, however. The final numbers of subjects evaluated 
were 8 and 9 for C and E groups, respectively. 
Urinary LH values were intended to be used to define cycle days 
as well as to determine integrated LH secretion. Marked variability 
of the results remains unexplained, however, and has precluded the 
usefulness of the data. The values are, therefore, not included in 
the data analysis. 
Results of the resting metabolic rate (RMR) measurements were 
determined to be nonrepresentative of resting metabolism. In spite of 
repeated measures on separate days in cases where the validity of ini­
tial values was questionable, values for some subjects were unusually 
high. The r^ values for some subjects were also elevated above normal 
resting values. Travel from home to the Human Performance Laboratory, 
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as well as the subjects' emotional state, apparently exerted a marked 
effect upon the measurement of RMR. Hence, this variable has been 
omitted from statistical analysis. 
Baseline Comparisons 
Wilcoxon two-sample tests were used to evaluate baseline (TP 
I) equality between C and E. Descriptve statistics of selected 
characteristics of C and E subjects are provided in Table 3. There 
were no statistically significant differences between C and E subjects 
with respect to age, height, weight, sum of skinfolds, percent body 
fat as determined by hydrostatic weighing, maximal oxygen uptake, and 
body weight lost since beginning running. The difference between C 
and E in total energy expenditure, per day, and per kg body weight, 
was not statistically significant (Table 3). The median expenditure 
for C subjects was 2505 kcal/day and 44.9 kcal/kg. The median expen­
diture for E was 2886 kcal per day and 47.8 kcal/kg. The accuracy of 
the method used to estimate energy expenditure is believed to be 
somewhat diminished in a highly active population (C. Bouchard, per­
sonal communication, October 10, 1983), and is probably not 
appropriate for a precise determination of energy balance (Bouchard et 
al., 1983). The magnitude and direction of error is assumed to be 
constant throughout the four test periods. For this reason, the 
values are used for comparison between and within these two groups, 
but are not considered valid for comparison to other populations and 
cannot necessarily be interpreted as absolute values. 
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Table 3 
Baseline Characteristics of Subjects 
E (n=9) 
Variable Median ~~ (Range) Median (Range) 
Age, yr. 33.5 (21-40) 31.6 (21-36) 
Height, cm 166.0 (161-175) 167.0 (160-170) 
Weight, kg 54.9 (48.5-71.4) 58.9 (52.8-71.9) 
SSF, mma 49.5 (30-93) 47.0 (30-82) 
% Body Fat*3 26.2 (20.5-34.0) 22.4 (15.6-29.4) 
VO2 Max, 
ml»kg»min~l 43.5 (34-54) 43.0 (34-56) 
Lb lost since 
beginning 
running 0.0 (0-12) 0.0 (0-13) 
Average Kcal 
expenditure0 
per day 2505 (1935-3042) 2886 (2525-3247) 
per kg 44.9 (39.2-52.5) 47.8 (40.9-51.8) 
aSum of 4 skinfold sites; triceps, bic eps, subscapular, and suprailiac 
^As determined by body density estimation by hydrostatic weighing, 
using the formula of Bro£ek (1963) 
cEstimated according to the method of Bouchard et al. (1983) 
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Menstrual history of the subjects is provided in Table 4. 
Similar values were observed between C and E for the age of menarche, 
history of dysmenorrhea, and number of pregnancies. Two C and four E 
subjects reported some degree of menstrual irregularity prior to the 
year immediately preceding their participation in the study, although 
these differences in frequency were not statistically significant. 
Three C and one E had experienced some change (not described) in their 
menstrual cycles since beginning running (again, a nonsignificant 
difference). Menstrual characteristics at TP I are provided in 
Table 5. The median length of menstrual cycles among C was signifi­
cantly longer than that of E; 29.5 vs. 26.0 days (ranges 26-36 and 
24-33 days; £<.05). The median number of days in which plasma P con­
centration was below 4.0 ng/ml among C subjects (15.0) was greater 
than that of E subjects (9.0) (JD<.05). These baseline differences 
cause concern for comparability between the two groups. However, no 
other differences between C and E were observed in plasma P con­
centrations as categorized in Table 5, nor in luteal phase length as 
indicated by the number of days from the surge of serum LH to the 
plasma P peak (Table 5). 
Running history differed in one respect between C and E (Table 
6). The reported number of weeks per year that subjects ran was 
greater among C than E (JD<.01). This difference can be attributed to 
three E subjects, one of whom reported running 36 weeks per year. 
This measure is a misleading indicator of physical activity for this 
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Table 4 
Menstrual History 
Variable C (n=8) E (n=9) 
No. of subjects 
with history of 
dysmenorrhea 
No. of subjects 
with history of 
dysfunction 
No. of subjects reporting 
change in cycle since 
beginning running 
Median age at menarche, yr 
Median no. of pregnancies 
13.0 (range 12-14) 
0.5 (range 0-2) 
13.0 (range 11-16) 
0.0 (range 0-2) 
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Table 5 
Menstrual Characteristics at the Onset of the Study 
C (n=8) E (n=9) 
Variable ; Median (Range) Median (Range) 
Usual no. 
of flow days 5.0 (3-8) 5.0 (2-7) 
No. of days 
from LH peak 
to P peak 6.0 (4-8) 8.0 (4-10) 
P conc 
> 6.0 ng/mla 1.0 (0-7) 5.0 (0-11) 
P conc of 4.0-
5.9 ng/mla 2.0 (0-4) 1.0 (0-4) 
P conc < 4.0 
ng/mla* 15.0 (10-2) 9.0 (6-24) 
Area under 
curve, 
P vs. time 53.0 (28.4-1.1) 57.0 (7.9-166.4) 
TP 1 cycle 
length, days* 29.5 (26-3) 26.0 (24-33) 
aValues provided represent number of days in which plasma P concentra­
tions were in the range indicated. 
•Significant difference between C and E (£<.05) 
Table 6 
Running History 
G (n=8) E (n=9) 
Variable Median (Range Median (Range) 
Age began 
running, yr 30.0 (18-40) 22.0 (17-36) 
Time since begin­
ning running, 
months 36.0 (4-68) 12.0 (3-156) 
Min/day run 37.5 (30-50) 40.0 (30-60) 
Day /week run 5.0 (4-6) 6.0 (3-6) 
Week/year run* 52.0 (50-52) 50.0 (30-52) 
Miles/week run 18.5 (15.22) 20.0 (10-23) 
Hours/year run 159.7 (125-195) 150.0 (60-300) 
•Significant difference between C S E (]3< .01) 
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subject, however, because during most of the 16 nonrunning weeks she 
participates in downhill skiing several times a week. The values 
reported by subjects 21 and 22, 30 and 44 weeks per year, respec­
tively, are likely to be valid representations of their running 
histories. To further evaluate the usual amount of time spent 
running, a variable derived from the number of minutes per day, days 
per week, and weeks per year spent running was computed. These three 
variables were multiplied together, and the product divided by 60 
minutes to yield the total number of hours run per year. The median 
value for C was not significantly different from that of E (159.7 vs. 
150.0 hours per year, respectively). 
Time per day and days per week spent running were similar 
between C and E. There were no significant differences in the length 
of time since subjects had first started running, nor in the age at 
which subjects began running, but ranges were large for both 
variables. Both groups ran a similar number of miles per week (MPW) 
at the beginning of the study. The median MPW for C was 18.5 MPW 
(range 1522), and for E, 20.0 MPW (range 10-23). 
Baseline dietary variables are presented in Table 7. The pro­
tein percentage of total kcal was greater among C than E at TP I 
(13.4% vs. 11.0%) (£<.05). Accordingly, the protein intake per 1000 
kcal was also significantly greater among C than E at TP I (33.4 
g/1000 kcal vs. 27.4 g/1000 kcal; £<.05). The difference in pro­
tein intake expressed per kg of body weight was not statistically 
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Table 7 
Baseline Dietary Variables 
Variable 
C (n=8) 
Median (Range) 
E (n=9) 
Median (Range) 
Kcal intake 
per day 
per kg 
Proteih 
g/day 
% of kcal* 
g/kg 
g/1000 kcal* 
Carbohydrate 
g/day 
% of kcal 
Fat, 
g/day 
% of kcal 
Saturated 
fat, g 
Polyunsaturated 
fat, g 
Cholesterol, 
mg 
Fiber, g 
Iron, mg 
Zinc, mg 
1683 (1392-2361 
31.2 (19.5-48.7) 
56.6 (49.9-90.8) 
13.4 (10.0-16.8) 
1.00 (0.78-1.87) 
33.4 (25.0-41.9) 
215.0 (172-317) 
44.2 (31.9-88.2) 
70.4 (41.3-85.1) 
34.4 (24.0-40.3) 
26.0 (13.3-35.2) 
38.4 (22.0-48.8) 
275.0 
6.1 
12.8 
6.8 
(77-536) 
(3.4-8.4) 
(6.9-23.5) 
(4.9-14.7) 
1816 (741-2769) 
32.7 (12.8-43.8) 
44.2 (26.6-92.0) 
11.0 (8.1-14.3) 
0.78 (0.46-1.46) 
27.4 (20.3-35.9) 
240.0 (126-382) 
49.5 (39.2-77.3) 
62.4 (17.1-121.7) 
32.5 (20.8-39.6) 
23.3 (4.7-57.5) 
35.0 (8.4-59.0) 
255.0 
6.1 
10.6 
8.4 
(34-546) 
(4.1-8.4) 
(5.8-19.8) 
(4.0-15.8) 
•Significant difference between C and E (£<.05) 
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different, however. No other significant differences were observed in 
dietary variables between the two groups. 
No between-group differences were observed in any biochemical 
values measured at TP I, including hemoglobin, hematocrit, serum 
ferritin, serum cholesterol, plasma zinc, and urinary 3-MH/creatinine 
excretion (Table 8). Considerable controversy exists as to the normal 
range of 3-MH excretion, and few studies have included female sub­
jects. The values reported in the current study, however, are con­
sistent with reports of previous investigations (Frisch et al., 1984; 
Munro, 1978). 
To summarize, the baseline comparisons between C and E confirmed 
equality on most variables. Statistically significant differences 
were observed, however, for the following variables: (a) the usual 
length of the menstrual cycle (Table 5), (b) the number of days in the 
TP I cycle in which plasma P concentration was less than 4.0 ng/ml 
(Table 5), (c) weeks run per year (Table 6), and (d) protein consump­
tion expressed as percent of total kcal and as g/kg body weight (Table 7). 
Menstrual Characteristics at Test Periods I and IV 
Changes in menstrual characteristics including P values are pre­
sented in Tables 9 and 10. As confirmed by the Wilcoxon signed-ranks 
test, the length of the luteal phase did not change for C or E sub­
jects between TP I and TP IV. There was no change in the median 
length of the menstrual cycle for either group, and the usual number 
of flow days remained unchanged as well. 
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Table 8 
Baseline Biochemical Comparisons 
C (n=8) E (n=9) 
Variable Median (Range) Median (Range) 
Hemoglobin, 
g/dl 13.4 (11.0-14.8) 13.4 (12.8-14.5) 
Hematocrit, % 40^5 (37.5-45.0) 41.0 (39.5-45.0) 
Serum 
ferritin, 
ng/ml 24.0 (1-71) 27.0 (3-79) 
Serum 
cholesterol, 
mg/dl 173.5 (132-253) 185.0 (158-231) 
Plasma zinc, 
mcg/dl 85.0 (78-110) 92.0 (84-108) 
Urinary 
3-MH/creati-
nine, nmol/mg 133.8 (68.5-236.7) 133.7 (82.3-219.1) 
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Table 9 
Menstrual Characteristics of Control Subjects, 
Test Period I vs. IVa 
I IV 
Variable Median Median Change 
Usual no. 
of flow days 5.0 5.0 0.0 
No. of days 
from LH peak 
to P peak 6.0 7.0 0.0 
P conc 
> 6 . 0  n g / m l b  1 . 0  0 . 0  0 . 0  
P conc of 4.0-
5.9 ng/mlb 2.0 0.0 -1.0 
P conc <4.0 
ng/mlb 15.0 19.0 +2.0 
Area under 
curve, 
P vs. time 53.0 25.3 -16.6* 
Cycle length, 
days 29.5 28.0 -4.0 
aTP I n=8; TP IV n=7 
^Values provided represent number of days in which plasma P 
concentrations were in the range indicated 
•Significant decrease from TP I to IV (£<.05) 
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Table 10 
Menstrual Characteristics of Experimental Subjects, 
Test Period I vs. IVa 
I IV 
Variable Median Median Change 
Usual no. 
of flow days 5.0 5.0 0.0 
No. of days 
from LH peak 
to P peak 8.0 6.0 0.0 
P conc 
> 6 . 0  n g / m l b  5 . 0  0 . 0  - 5 . 0 *  
P conc of 4.0-
5.9 ng/mlb 1>0 0.0 -1.0 
P conc <4.0 
ng/mlb g.o 16.0 +6.0 
Area under 
curve, 
P vs time 57.0 21.2 -22.6 
Cycle length, 
days 26.0 27.0 +1.0 
an=9 
^Values provided represent number of days in which plasma P 
concentrations were in the range indicated 
•Significant decrease from TP I to IV (p< .05) 
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Among E subjects there was a statistically significant decrease 
in the number of days in which P concentrations were greater than 6.0 
ng/ml (g<.05). The E median number of days of high P concentrations 
decreased from 5.0 days in TP I to 0.0 days in the last test 
period. 
Among the C subjects, the area under the P-vs.-time curve 
decreased significantly (£<.05) from TP I to IV (53.0 units to 26.7 
units). The P area under the curve also decreased among the E sub­
jects (57.0 units to 21.2 units), but the change was not statistically 
significant, probably due to the wide variability of observations. 
A Wilcoxon two-sample test was performed to compare the degree 
of change of P variables between the two groups. The results con­
firmed that the magnitude of change among E did not differ signifi­
cantly from that of C for any of the P variables; area under the 
P-vs-time curve; number of days in which P concentration was greater 
than 6.0 ng/ml, 4.0-5.9 ng/ral, or less than 4.0 ng/ml; and the number 
of days between the LH surge and the P peak. 
Anthropometric Measures and Variables Related to 
Exercise, Test Period I to Test Period IV 
Anthropometric measures as well as exercise-related variables 
are presented in Tables 11 and 12. Experimental subjects ran a 
greater number of MPW than C at TP II, III, and IV; however, 
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Table 11 
Median Values of Anthropometric and Physical Activity Measures 
for Control Subjects, Test Period I through IV 
I II III IV 
Variable Median Median Median Median 
Miles run 
per week 18.5 14.5 13.5 17.0** 
Energy expenditure3 
per day 2505 2579* 2723 ' 2621** 
per kg 44.9 44.1* 48.8 47.1 
Weight, kg 54.9 54.9 55.7 55.7 
SSF, mmb 49.5 51.5 53.0 49.5 
% Body fatc 26.2 25.1 25.6 27.5 
• 
VC>2 max, 
ml'kgTnin"! 43.5 41.5 
aEstimated according to the method of Bouchard et al. (1983) 
^Sum of 4 skinfold sites; triceps, biceps, subscapular, and suprailiac 
cAs determined by body density estimation by hydrostatic weighing, using 
the formula of Brozek (1963) 
•Statistically significant difference from E group (|><.05) 
**Statistically significant difference from E group (p< .01) 
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Table 12 
Median Values of Anthropometric and Physical Activity Measures 
for Experimental Subjects, Test Period I through IV 
I II III IV 
Variable Median Median Median Median 
Miles run 
per week 20.0 20.0 29.0 32.0**t 
Energy expenditure3 
per day 2886 2928# 2897 2997^ 
per kg 47.8 49.0* 49.4 48.7t 
Weight, kg 58.9 59.0 60.8 59.1 
SSF, mm*5 47.0 44.0 45.0 46.0 
% Body fatc 22.4 21.9 23.8 23.5 
VC>2 max, 
ml«kg*min~l 43.0 45.0 
aEstimated according to the method of Bouchard et al. (1983) 
^Sum of 4 skinfold sites; triceps, biceps, subscapular, and suprailiac 
cAs determined by body density estimation by hydrostatic weighing, using 
the formula of Bro£ek (1963) 
•Statistically significant difference from C group (g<.05) 
••Statistically significant difference from C group (p< .01) 
tStatistically significant difference from TP I (£<.05) 
ftStatistically significant difference from TP I (jac.Ol) 
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statistical significance of this difference was not achieved until the 
last test period (32 MPW vs.. 17 MPW; £<.01). By TP III and IV, the 
E subjects were running 45% and 60% more MPW, respectively, than at 
baseline. The variability in MPW among E rose progressively as their 
mileage increased. The large variability was primarily attributable 
to injuries, which necessitated a slower rate of increase in mileage 
among some subjects than others. 
The difference between C and E in estimated daily energy expen­
diture, expressed per kg of body weight, was statistically significant 
only at TP II (44.1 kcal/kg for C and 44.9 kcal/kg for E; £<.05). 
The total daily energy expenditure, however, was significantly greater 
among E than C at TP II (2928 kcal/day vs. 2579 kcal/day) and IV 
(2997 kcal/day vs. 2621 kcal/day; p<.05 and .01, respectively). Con­
trol subjects reported their greatest estimated energy expenditure 
during TP III (2723 kcal/day), although their running mileage (13.5 
MPW) was lower during that test period than in any other test period. 
Among E, the difference between the estimated total energy expenditure 
at TP I (2847 kcal/day) and at TP IV (2997 kcal/day) was not statisti­
cally significant. There was a significant increase in caloric expen­
diture per kg of body weight among E from TP I to IV; 47.8 kcal/kg at 
TP I to 48.7 kcal/kg at TP IV (£<.05). 
Measures of skinfold thicknesses, body density via hydrostatic 
weighing, and body weight indicated that body weight and fat levels 
remained relatively constant for both C and E throughout the study. 
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There were no statistically significant differences between the two 
groups on any of the anthropometric measures at any test period. 
The median VO2 max achieved by C at TP IV decreased slightly from that 
of TP I (43.5 ml/kg to 41.5 ml/kg). The E median VO2 max increased 
marginally from 43.0 ml/kg at TP I to 45.0 ml/kg at the end of the 
study. Neither change was statistically significant. 
Dietary Intake, Test Period I to Test Period IV 
The median values of dietary variables are provided in Tables 13 
and 14. Out of all of the dietary variables evaluated, C and E dif­
fered significantly only on protein intake. At TP I, the proportion 
of kcal derived from protein among C was 13.4%, while that of E was 
11.0% (]3<.05). Protein intake expressed as g/1000 kcal was greater 
among C than E at TP I (33.4 g/1000 kcal vs. 27.4 g/1000 kcal; £< 
.05). The change from TP I to IV in protein intake was significantly 
different between C and E (j><.01). While E subjects consumed 2.5 g 
more protein per 1000 kcal, the protein intake of C decreased by a 
median of 2.4 g per 1000 kcal. The difference in protein intake 
expressed per kg of body weight, or as total daily intake, was not 
statistically significant, however, at any test period. 
The total daily kcal intake of E subjects appeared to increase 
slightly from TP I to IV (1816 kcal/day to 1918 kcal/day), but was 
not statistically significant. The kcal intake per kg of body 
weight among E remained constant at 32.7 kcal/kg. The median kcal 
intake of C also increased by 100 kcal per day, from 1683 kcal/day 
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Table 13 
Median Values of Dietary Intake of Control Subjects 
Test Period I through IV 
Variable 
I 
Median 
II 
Median 
III 
Median 
IV 
Median 
Kcal intake 
per day 1683 
per kg 31.2 
Protein 
g/day 56.6 
% of kcal* 13.4* 
g/kg 1.00 
g/1000 kcal* 33.4* 
Carbohydrate 
g/day 215.0 
% of kcal 44.2 
Fat, 
g/day 70.4 
% of kcal 34.4 
Saturated 
fat, g 26.0 
Polyunsaturated 
fat, g 38.4 
Chole sterol, 
mg 275.0 
Fiber, g 6.1 
Iron, rag 12.8 
Zinc, mg 6.8 
1547 
27.7 
48.9 
13.1 
0.87 
32.8 
207.0 
42.6 
56.0 
34.0 
19.6 
29.4 
230.0 
4.7 
10.0 
6 . 2  
1638 
30.8 
51.9 
12.8 
0.88 
31.9 
219.0 
45.4 
51.7 
29.6 
17.0 
31.4 
221.5 
4.7 
10.6 
8.5 
1783 
33.7 
55.7 
13.0 
0.94 
32.4 
238.0 
49.0 
64.4 
32.3 
22.2 
35.8 
202.0  
6.4 
10.1 
8.3 
•Significant difference from E group (£<.05) 
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Table 14 
Median Values of Dietary Intake of Experimental Subjects, 
Test Period I through IV 
I II III IV 
Variable Median Median Median Median 
Kcal intake 
per day 1816 1569 1753 1918 
per kg 32.7 29.2 29.4 32.7 
Protein 
g/day 44.2 49.2 55.9 51.3 
% of kcal* 11.0* 11.2 11.7 12.3 
g/kg 0.78 0.90 1.00 0.95 
g/1000 kcal* 27.4* 28.0 29.4 30.8 
Carbohydrate 
g/day 240.0 23.5 237.0 233.0 
% of kcal 49.5 44.8 51.8 49.3 
Fat, 
g/day 62.4 55.3 67.9 72.7 
% of kcal 32.5 31.9 34.8 36.0 
Saturated 
fat, g 23.3 21.1 25.3 26.6 
Polyunsaturated 
fat, g 35.0 28.7 38.8 39.9 
Cholesterol, 
mg 255.0 231.0 284.0 279.0 
Fiber, g 6.1 5.9 6.9 7.1 
Iron, mg 10.6 12.5 12.0 13.3 
Zinc, mg 8.4 8.6 9.2 8.2 
•Significant difference from C group (g_<.05) 
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at TP I to 1783 kcal/day at TP IV. The median kcal/kg intake for C 
was 31.2 kcal/kg at TP I and 33.7 kcal/kg at TP IV. Neither measures 
of energy intake at TP IV were significantly different from TP I among 
C subjects. 
Although the estimated energy expenditure exceeds the kcal 
intake at every test period, the increase in energy intake reported 
for both C and E (although statistically nonsignificant), parallels 
the increase in the estimated energy expenditure from TP I to IV. The 
increment for each group is about 100 kcal per day. The median values 
of C and E subjects for all other dietary variables were similar bet­
ween TP I and IV. 
In spite of large difference in the medians, serum ferritin 
levels were not significantly greater among C than E at any test 
period, probably because of the large variability in each group 
(Tables 15 and 16). Serum ferritin decreased significantly among E 
subjects from 27.0 ng/ml at TP I to 5.0 ng/ml at TP IV (JD<.01). 
Excretion of 3-MH per mg of creatinine was significantly greater 
among C than E at TP II (241.1 nmol/mg vs. 147.1 nmol/mg; JD<.05). 
There were no other significant differences in any biochemical 
variables at any test period. 
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Table 15 
Median Biochemical Values for Control Subjects, 
Test Period I through IV 
I II III IV 
Variable Median Median Median Median 
Hemoglobin, 
g/dl 13.4 13.6 13.3 13.5 
Hematocrit, % 40.5 41.0 42.0 42.3 
Serum 
ferritin, 
ng/ml 24.0 15.0 16.5 21.5 
Serum 
cholesterol, 
mg/dl 173.5 171.5 174.0 181.0 
Plasma zinc, 
mcg/dl 85.0 85.0 96.5 91.0 
Urinary 
3-MH/creati-
nine, nmol/mg 133.8 242.1 137.0 141.8 
•Significant difference from E group (p< .05) 
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Table 16 
Median Biochemical Values for Experimental Subjects, 
Test Period I through IV 
I II III IV 
Variable Median Median Median Median 
Hemoglobin, 
g/dl 13.4 12.9 12.6 12.5 
Hematocrit, % 41.0 40.0 40.5 39.5 
Serum 
ferritin, 
ng/ml 27.0 9.5 9.0 5.0 
Serum 
cholesterol, 
mg/dl 185.0 170.0 184.0 175.0 
Plasma zinc, 
mcg/dl 92.0 90.0 95.0 90.0 
Urinary 
3-MH/creati-
nine, nmol/mg 133.7 147.1* 166.0 141.1 
•Significant difference from C group (p<.05) 
tSignificant difference from TP I (g<.01) 
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CHAPTER V 
DISCUSSION 
The present investigation was implemented to test hypotheses 
that were based upon the assumption that a program of progressive 
exercise will result in alterations in reproductive hormone function 
in female recreational runners. Although changes in plasma P con­
centrations were observed among subjects participating in the 
progressive running program, the hypotheses can not be specifically 
addressed due to the changes in progesterone concentrations also 
observed among C subjects, which were of a similar magnitude and 
direction. The changes that occurred in the plasma P concentrations 
among E subjects, therefore, can not be attributed to their increase 
in exercise quantity or intensity. 
Menstrual Characteristics 
At TP I, the length of the menstrual cycle was significantly 
longer among C than E. In addition, the number of days in which P 
concentrations were below 4.0 ng/ml was greater among C than E. The 
latter difference may be a reflection of the longer cycles; neverthe­
less, these baseline difference raise the question of comparability 
between the two groups with respect to menstrual function. The non-
normal distribution of the sample and the small sample size precluded 
the use of Chi square or regression analysis to control for baseline 
differences. A limited type of covariate analysis was attempted, 
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however, by testing for significant differences between computed 
change variables (TP I to TP IV) for all of the P-related variables. 
By comparing the degree of change from TP I to IV within C to that of 
E, one controls for the starting point of each observation. 
Another concern regarding the baseline endocrine data is the low 
P values observed for 3 of the subjects. One C subject (15) and 2 E 
subjects (3 and 23) had no measured P concentrations in the mid- or 
high-P range (4.0 ng/ml or greater) at TP I. Thus, these subjects 
appear to have had compromised luteal function at the onset of the 
study. The subjects demonstrating low P concentrations at TP I are 
3 of the 4 subjects whose P area change scores increased from TP I 
to IV, in contrast to the decreases exhibited by all of the other 
subjects. Removing the data of subjects 3, 15, and 23 from statisti­
cal analyses did not alter the outcome of statistical tests between 
the two groups because the resulting small sample size severely limits 
the power of statistical tests. 
The median number of flow days and the length of the menstrual 
cycle remained unchanged among C and E subjects. This lack of change 
was anticipated; no changes of these two variables associated with 
exercise training have been reported in the literature. The lack of a 
shortening of the luteal phase among E is inconsistent with cross-
sectional findings that have been reported for exercising vs. inactive 
women (Bonen et al., 1981; Ellison 6 Lager, 1985; Frisch et al., 
1984; Jacobson 6 Bonen, 1981; Jacobson et al., 1983; Prior et al., 
1982; Shangold et al., 1979). 
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Analysis of the individual data for changes in the length of the 
luteal phase reveals no clear trend among the subjects as a group 
(Table 17). There was considerable variability among the subjects 
with respect to changes that occurred in the length of time between 
the ovulatory LH surge and the P peak. 
The number of days in which P concentrations exceeded 6.0 ng/ml 
(Hi-P) in the menstrual cycles of E subjects decreased significantly 
from TP I to TP IV. The difference between the change experienced by 
E subjects and that of the C subjects was not statistically signifi­
cant, however. The changes in Hi-P days among C subjects were -6, -2, 
0, 0, 0, 0, and +3 days, with a median of 0.0 days. The observed 
changes in Hi-P days among E were -11, -8, -6, -5, -5, -3, 0, 0, and 
+4 days, with a median of -5 days. There is an obvious trend of 
decreasing Hi-P days among E, with little evidence any trend among C. 
The lack of a statistically significant difference between the two 
groups may be explained on the basis of the small sample size and a 
high degree of variability among the E subjects. Standard deviations 
for the Hi-P change scores were 2.8 and 4.6 days for C and Et respec­
tively. 
The decrease from TP I to IV in the area under the curve for 
P vs. time (P area) was statistically significant among G (£<.05), but 
not among E (£=.097). Six of the 9 E subjects experienced a decrease 
in P area ranging from a decrease of 13 units to 158 units, while the 
P area of 3 E subjects rose from TP I to IV, increments of 1, 7, and 
30 units. The decreases in the P area from TP I to IV among 6 C 
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Table 17 
Change in Weekly Running Mileage and Number 
of Days between LH Surge and Progesterone 
Peak, Test Period I to Test Period IV 
Subject MPWa Daysb 
2 +60% -4 
21 +90% -2 
16 +17% -1 
11 -29% 0 
15 +5% 0 
17 +6% 0 
7 +85% 0 
22 +21% 0 
4 -6% +1 
1 +100% +1 
9 -27% +2 
18 +45% +2 
6 +19% +4 
aMPW represents the percentage change in miles per week run from 
Test Period I to Test Period IV 
^Days represents the change in the number of days from the LH 
surge to the progesterone peak in the menstrual cycle of Test 
Period I to that of Test Period IV 
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subjects ranged froitn 14 to 44 units, and the P area increased 13 
units in 1 C subject. The tremendous variability in the P area 
changes from TP I to IV within the E group (standard deviations 
were 19.2 and 57.0 units for C and E, respectively) again contributed 
to the lack of a statistically significant difference between the two 
groups. As previously mentioned, 3 of the 4 subjects whose P area 
increased from TP I to IV exhibited inadequate luteal function at 
the beginning of the study. 
An important consideration with respect to comparisons of cir­
culating hormone levels between and among individuals is the degree to 
which circulating levels can be assumed to represent system function. 
Absolute values of circulating hormones provide no evidence of hormone 
turnover or of changes that may have occurred, for example, in the 
number of or the sensitivity of receptor sites. Thus, the absence of 
changes in circulating hormone levels does not rule out the possibi­
lity that changes in hormone turnover have occurred at either the site 
of hormone release or the target tissue. 
Running Mileage 
The difference between C and E in weekly running mileage was not 
statistically significant until the last test period, when the median 
distance run was 17 MPW and 32 MPW for C and E, respectively. The 
investigators' anticipated increase in running mileage among the E 
subjects was a minimum of 40 MPW by TP IV, achieving at least 30-35 
MPW by TP III. The median TP III mileage among E was 29 MPW, but 
with a relatively large degree of variability (SD=7.7 MPW) due 
78 
primarily to injuries among the runners. A more rapid increase in 
running mileage may have resulted in greater changes in the menstrual 
function variables measured. 
The protocol of the prospective study by Boyden et al. (1983) 
required the runners to increase their weekly mileage from 15 to 63 
MPW over 14 to 15 months, an average increment of less than 1 MPW. 
The authors reported measures of only 2 reproductive hormones: Basal 
testosterone concentrations remained unchanged in response to the 
progressive increase in running, and basal estradiol levels were 
reduced. The only clinical evidence of menstrual irregularities 
observed was in a diminution of blood loss due to both decreased 
volume of flow and to fewer flow days. Bullen et al. (1985) reported 
clinical or hormonal abnormalities of menstrual function in 31 of 32 
women participating in an 8-week program of progressive running. The 
runners increased their running distance from 20 to 50 MPW in 5 weeks, 
an increment of 7.5 MPW, and maintained 50 MPW through the 8th week. 
Perhaps a more rapid progression such as that used by Bullen et al. is 
more likely to induce changes in menstrual function. In the present 
study, the E subjects' weekly mileage averaged an increase of only 0.5 
MPW over approximately 7 months. 
The gradual progression of exercise training may result in the 
development of an adaptive mechanism to protect normal menstrual func­
tion. One observation of the present study supports this hypothesis. 
Omitting the subjects for whom plasma P concentrations indicated 
possible impairment of luteal function, Subject 22 was the only sub­
ject whose P area increased from TP I to IV. She was also unique 
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in that the length of time she had been running before participation 
in the study was greater than any of the other subjects. Subject 22 
had been running for 156 months (13 years) prior to the beginning of 
the study, whereas running experience among other participants ranged 
from 3 months to 84 months. Only 2 of these subjects reported running 
for more than 60 months (5 years). Elimination of the data of Subject 
22 in the E group, results in a statistically significant decrease 
between the P area in TP I and that of TP IV (£<.05). No definitive 
conclusions can be drawn from such an analysis; however, this obser­
vation does lend support to the hypothesis that the physiological 
adaptations to exercise may include a mechanism by which reproductive 
function is protected when exercise progression is gradual. 
Energy Drain 
The changes observed among G subjects are difficult to explain, 
given their relatively constant exercise levels for the duration of 
the study. By subjective evaluation, there were no apparent changes 
among C subjects with respect to stress levels, health, or general 
lifestyles across the four test periods. Although a negative energy 
balance among C subjects appears to be unlikely, the possibility of 
its occurrence needs to be addressed. The median energy expenditure 
of both groups was greater at TP IV than at TP I; however, the dif­
ference was statistically significant only for E (£<.05), whose 
running mileage also increased significantly (£< .01) (Table 18). 
During TP III, C reported their greatest energy expenditure, but their 
lowest MPW. This apparent discrepancy can probably be explained by 
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Table 18 
Median Values of Energy Intake 6 Expenditure, 
and Miles Run per Week, Test Periods I through IV 
Control Subjects I 
Kcal intake 
per day 1683 
per kg 31.2 
Kcal expenditure® 
per day 2505 
per kg 44.9 
Miles run/week 18.5 
"Energy deficit11*3 
per day -822 
per kg -13.7 
II III IV 
1547 1638 1783 
27.7 30.8 33.7 
2579 2723 2621 
44.1 48.8 47.1 
14.5 13.5 17.0 
-1032 -1085 -838 
-16.4 -18.0 -13.4 
Experimental Subjects 
Kcal intake 
per day 1816 1569 1753 1918 
per kg 32.7 29.2 29.4 32.7 
Kcal expenditure3 
per day 2886 2928 2897 2997 
per kg 47.8 49.0 49.4 48.7 
Miles run/week 20.0 20.0 29.0 32.0 
"Energy deficit"*3 
per day -1070 -1359 -1144 -1079 
per kg -15.1 -19.8 -20.0 -16.0 
aAs estimated using the method of Bouchard et al. (1983) 
bThe difference between energy intake and estimated energy expenditure 
has been calculated for relative comparisons only. The estimated 
energy expenditure is not necessarily representative of actual energy 
expenditure; hence, a true energy balance cannot be ascertained from 
the data. 
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the time of the year of TP III; for most subjects, TP III coincided 
with the the time of the year of TP III; for most subjects, TP III 
coincided with the beginning of spring. It is feasible that 
nonrunning energy expenditure did increase as a result of more outdoor 
activities such as walking, bicycling, yardwork, and tennis. 
No significant changes in measures of body weight, skinfold 
thickness, or in body density as estimated by hydrostatic weighing 
were observed among C or E. A reduction of basal metabolic rate in 
response to caloric restriction has been documented in animals and in 
humans (Apfelbaum, Bostsarron, 6 Lacatis, 1971; Hill, Fried, 5 
DiGirolamo, 1984; Miller 5 Parsonage, 1975), thereby making possible 
the maintenance of a constant body weight and fat level in spite of an 
energy intake that seems incompatible with energy expenditure. Energy 
intakes that seem insufficient to meet energy demands have been 
reported for runners and dancers (Berning et al., 1975; Calabrese et 
al., 1983). The estimated energy expenditures of C and E in the pre­
sent study indicate large energy deficits for both groups; yet, the 
instrument that was used to estimate energy expenditure (Bouchard et 
al., 1983) has not been validated in a highly active population, and 
can not be considered to provide a precise estimate of caloric expen­
diture. (Reliability of the instrument within this sample appears to 
be good as judged by the fact that median changes of estimated energy 
expenditure paralleled median changes in caloric intake.) The 
measurement of RMR was intended to be helpful in addressing the 
question of metabolic adaptation. Unfortunately, RMR data provided 
invalid measurements of resting metabolism among these women. 
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To test the possibility of an effect of energy balance on 
variables relating to menstrual function, an energy ratio was computed 
for each subject (ratio of energy intake to energy expenditure). No 
significant correlations (Kendall Tau) were detected between any of 
the P-related variables (absolute values or change scores) and the 
energy ratio. 
An indirect measurement of caloric insufficiency is urinary 
3-MH, a natural marker of skeletal muscle metabolism (Lukaski 9 
Mendez, 1980). This amino acid is found almost exclusively in skele­
tal muscle. During catabolism, 3-MH. is not oxidizable (Long et al., 
1975), nor is it reincorporated into protein (Young, Alexis, Baliga, 5 
Munro, 1970). Measurement of urinary 3-MH provided no evidence of 
accelerated breakdown of skeletal muscle tissue among runners in the 
present study. Values were consistent with those previously reported 
for women (Frisch et al., 1984; Munro, 1978). Tests of correlation 
revealed a significant association between 3-MH excretion and MPW 
among E subjects at TP I (j3< .05). The association was considered to 
be artifactual, however, because there were no other significant 
correlations between MPW and 3-MH excretion at any test period in 
either group. Thus, the available data do not support the possibility 
of an energy deficit among C or E subjects. 
The 3-MH excretion among C deserves mention. At TP II, the C 
group excreted 242.1 nmol 3-MH/mg creatinine, a substantial increase 
over values of TP I (133.8 nmol/mg), TP III (137.0 nmol/mg), and 
TP IV (141.8 nmol/mg). The 3-MH excretion was significantly 
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greater among C than E (147.1 nmol/mg) at TP II (£<.05). Although 
an increased urinary 3-MH excretion has been reported in response to 
intensive exercise training (Frisch et al., 1984), the TP II 
increase in 3-MH excretion among C can not be explained by running 
mileage; C subjects reported their lowest weekly mileage during TP 
II (Table 18). Control subjects also reported their lowest kcal 
intake during TP II, but this was not the test period with the 
greatest apparent discrepancy between caloric intake and expenditure 
(Table 18). Furthermore, tests of correlation revealed no consistent 
associations with energy intake or expenditure. The high 3-MH excre­
tion by C subjects at TP II remains unexplained. 
Fiber Intake 
The increased fecal bulk resulting from a high-fiber vegetarian 
diet has been proposed as a possible contributing factor to the deve­
lopment of menstrual dysfunction (Slavin et al., 1984). In the pre­
sent study, the highest median intakes of dietary fiber reported by C 
and E subjects respectively, were 6.4 g/day and 7.1 g/day, both at 
TP IV. This level is well below the daily intake of 28 g of dietary 
fiber that was associated with altered estrogen metabolism among vege­
tarian women (Goldin et al., 1982), and below the dietary fiber intake 
of 12 g/day among vegetarian men who exhibited alterations in testos­
terone and estrogen metabolism (Howie S Shultz, 1985). There is 
little information available regarding the fiber intake of the U. S. 
population. In one study of 200 students, dietary fiber intake 
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averaged 15.4 g/day (Marlett 8 Bokram, 1981), more than twice the 
amount of fiber consumed by subjects in the present study. Dietary 
fiber intake among C and E subjects apparently did not increase con­
comitant with their change to a vegetarian diet. 
Fat Intake 
The median daily fat consumption among C ranged from 51.7 g/day 
to 70.4 g/day, comprising 29.6% to 34.4% of total kcal. Among the E 
subjects, the median fat intake ranged from 55.3 g/day to 72.7 g/day, 
corresponding to a percentage of total kcal of 31.9% to 36%. This 
level of dietary fat is below the mean fat intake reported for young 
women in the U. S. (90-100 g/day; 40% of total kcal) (Goor et al., 
1985). it is not known if the fat consumption among the C and E sub­
jects declined significantly while participating in the study from 
their customary prestudy level of intake; however, the nonsignificant 
changes in serum cholesterol levels suggest that the fat intake of C 
and E subjects did not change quantitatively or qualitatively from 
their prestudy diets. The relatively small difference between the fat 
intake among the runners and that of average American women, would not 
seem to be a likely cause of the changes in P concentrations observed. 
Protein Intake 
Protein consumption exceed the RDA of 0.8 g protein/kg body 
weight (National Research Council, 1980) for all test periods except 
TP I, during which the protein intake among E subjects was 0.78 
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g/kg. While this level of dietary protein appears to be adequate, 
protein balance can not be ascertained from food records alone, espe­
cially in the absence of energy balance determinations, and without 
characterizing and quantifying the protein quality of the diet. The 
relatively constant levels of 3-MH excretion indicate that skeletal 
muscle metabolism was not accelerated, suggesting that protein nutri-
ture was sufficient. 
The question of whether there is some component of a vegetarian 
diet that affects reproductive function remains to be answered. 
Alterations in P concentrations were observed among the subjects; 
however, the data do not support the hypothesis that such changes are 
attributable to exercise. Based on the dietary variables available 
for analysis, no dietary element can be implicated as a contributor to 
the measured P effects. Nevertheless, the role of diet in the deve­
lopment of menstrual disorders can not be discounted as a potential 
causative factor. 
Summary 
No significant changes were observed among C or E subjects with 
respect to body weight, skinfold thickness, body density, or maximal 
oxygen uptake from TP I to TP IV. The E runners increased their 
energy expenditure (47.8 kcal/kg to 48.7 kcal/kg) and running mileage 
(20 MPW to 32 MPW) significantly. The serum ferritin levels of E sub­
jects declined markedly from 27.0 ng/ml TP I to 5.0 ng/ml at TP IV. 
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The diets of the two groups differed only in protein intake at 
TP I, E subjects consuming slightly less protein than C subjects 
(27.4 g/1000 kcal vs. 33.4 g/1000 kcal). At TP I, significant dif­
ferences between C and E were observed for the length of the menstrual 
cycle and for the number of days in which plasma P concentrations were 
less than 4.0 ng/ml. In an effort to control for these baseline dif­
ferences in subsequent comparisons between the two groups, TP-I-to-
TP-IV change scores were computed. 
Among E subjects there was a significant decrease in the number 
of days in which plasma P concentrations were greater than 6.0 ng/ml, 
whereas C subjects experienced a significant decrease in the area 
under the curve for P vs. time. No significant correlations were 
observed between any of the P-related variables and weekly running 
mileage or energy expenditure across the four test periods. Nor was 
there a signifcant decrease in luteal phase length among E, as 
observed among females participating in other studies of progressive 
exercise. None of the changes in P variables was significantly dif­
ferent between C and E, suggesting that the alterations observed in P 
levels were not due to exercise, but rather to some unidentified fac­
tor common to both C and E subjects. 
It is likely that the etiology of athletic amenorrhea is multi­
factorial. The possibility exists that individual variability 
accounts for much of the contrasting responses to exercise among 
women. Analagous to the recent recognition that there are hyper- and 
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hyporesponders to dietary cholesterol in terras of a serum cholesterol 
effect (Oh 6 Miller, 1985), perhaps there are some women whose 
response to exercise results in impairment of the reproductive system, 
whereas other women are unaffected. It is feasible also, that an 
adaptive mechanism to protect against menstrual dysfunction is opera­
tive in some women and not in others. Following are some suggestions 
for further research based upon the outcome of the present study and 
on the questions raised as a result of these findings. 
Suggestions for Further Research 
Possibly the most important addition to the protocol of the pre­
sent study would be a prestudy control period of 2-6 months. During 
this time, . records would be collected on customary exercise practices 
and dietary intakes. Menstrual records during the control period 
would provide evidence of normal menstrual patterns. Hormonal eva­
luation should be included as well. Only subjects demonstrating unam­
biguously normal menstrual function would be accepted to participate 
in the study. 
A valuable characteristic of the present study was the use of a 
free-living population. This is desirable to minimize stress and 
lifestyle-change effects on menstrual function. In one study of the 
effects of progressive running on menstrual function, the subjects 
were moved to a summer camp for the duration of the study (Bullen et 
al., 1985). The study protocol has been criticized because of the 
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possibility that the menstrual abnormalities observed were related to 
the disruption of the subjects' customary living patterns (Metcalf, 
1985). 
An obvious advantage of the summer camp environment is that the 
subjects can more readily devote time and energy to exercise, free 
from family, work, school, or community-related responsibilities. 
This is an important consideration, and may warrant the dislocation of 
the subjects to such an environment if exercise demands are severe. 
To induce an observable menstrual response to exercise, it is probably 
desirable to intensify the exercise level much more rapidly than the 
progression of the present study. If subjects are moved from their 
normal habitat to participate in the study, a control group who main­
tain their customary residence should be incorporated to the study. 
In contrast to the two prospective studies of exercise-related 
menstrual dysfunction previously reported (Boyden et al., 1983; Bullen 
et al., 1985), the present study included a control group who did not 
increase their running. If the sample size were adequate, 2 experi­
mental and 2 types of control groups would allow for the separate eva­
luation of the effects of diet and the effects of exercise on 
menstrual function. For example, 1 of the 2 groups whose training 
mileage remained constant would maintain a normal nonvegetarian eating 
pattern, and 1 group would change to a vegetarian diet. There would 
also be a vegetarian and a nonvegetarian group participating in a 
program of progressive running. 
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A large sample size would provide greater statistical power for 
within-group and between-group comparisons. A sample size of 100 
would be ideal, and could probably be achieved through coordinated 
efforts between investigators at various geographical localities. A 
project of such proportion would require extensive personnel, an 
aspect of the present study that severely limited the data collection 
capabilities of the investigators as well as the management of the 
subjects, i.e., coaching and motivating the runners. 
Daily blood samples rather than every other day, which were 
precluded in the present study due to limited resources, would greatly 
enhance the value of the hormone data. The use of salivary P con­
centrations (Ellison & Lager, 1985) should be explored as a means 
of simplifying data collections. 
The issue of energy drain can not be adequately addressed 
without improved methods of estimating, or simplified methods of 
measuring energy expenditure. The use of devices such as a portable 
accelerometer (Montoye et al., 1983) should be explored. In addition, 
the accurate evaluation of resting or basal metabolic rate would be 
useful. 
Few studies of exercise-related dysfunction have included a 
dietary component. The effects of protein quality, nitrogen balance, 
and energy balance on menstrual function need to be investigated. Fat 
levels of the diet as well as the quality of the fat have not yet been 
assessed in relation to exercise-associated menstrual dysfunction. 
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Mineral nutriture, i.e., iron, as demonstrated in the present study, 
is affected by exercise, and also warrants further investigation. In 
short, there is a strong need for nutrition research in the search for 
a better understanding of athletic amenorrhea. Nutrition researchers 
must work together with endocrinologists and exercise physiologists in 
the development of research designs and in the analysis and interpre­
tation of dietary evaluation. 
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wmstt nvmsits 
NEEDED TO PARTICIPATE IN 6-MONTH TRAINING STUDY 
LEARN MORE ABOUT YOUR OWN : 
° FITNESS LEVEL 0 CALORIC INTAKE 
° % BODY FAT ° ENERGY EXPENDITURE 
THE STUDY HAS 2 COMPONENTS: 
(1) FOR WOMEN WHO WANT TO INCREASE THEIR CURRENT LEVEL OF TRAINING. & 
(2) FOR THOSE WHO WANT TO MAINTAIN THEIR CURRENT LEVEL OF RUNNING. 
THE OBJECTIVES OF THE STUDY ARE TO (1) DETERMINE HORMONE RESPONSES TO 
EXERCISE TRAINING S (2) INVESTIGATE DIETARY PATTERNS AMONG WOMEN RUNNERS. 
SUBJECTS WILL EITHER BE PROGRESSIVELY TRAINED OVER A 6-MONTH PERIOD TO 
INCREASE RUNNING DISTANCE & INTENSITY OR THEY WILL MAINTAIN A CONSTANT 
LEVEL OF EXERCISE THROUGHOUT THE 6-MONTH PERIOD. 
SUBJECTS SHOULD BE ° FEMALES, AGE 18-35 
O CURRENTLY RUNNING 15-25 MILES/WEEK FOR AT LEAST 
6 MONTHS PRIOR TO THE STUDY 
0 NONSMOKERS. NONUSERS OF ORAL CONTRACEPTIVES 
O FREE OF METABOLIC DISEASE 
THE STUDY IS SCHEDULED TO BEGIN IN NOVEMBER. 1983. FOR MORE INFORMATION, 
CONTACT JEANNIE CRANE OR DR. TERRY BAZZARRE IN THE UNC-G NUTRITION DEPT. 
ANY WEEKDAY BEFORE H PM (379-5332). OR PHONE 275—4220. 
THE UNIVERSITY OF NORTH CAROLINA 
AT GREENSBORO 
School of Homt Economics 
Difartmtnt at Food-Nutrition-Food Sttvict Maxagtnunt 
(919) 379-5332: 5313 
° HORMONE RESPONSE 
TO EXERCISE 
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THE UNIVERSITY OF NORTH CAROLINA 
AT GREENSBORO 
School of Horn* Eeonomia 
WOMEN RUNNERS NEEDED 
TO PARTICIPATE IN A 6-MONTH TRAINING STUDY 
IF YOU'RE A FEMALE, AGE 18-35. CURRENTLY RUNNING 15-25 MILES 
PER WEEK, AND WOULD LIKE TO IMPROVE YOUR RUNNING AND FITNESS LEVEL/ 
HERE'S YOUR CHANCE: I'M RECRUITING SUBJECTS FOR A STUDY IN WHICH WE 
WILL INVESTIGATE DIETARY PATTERNS AS WELL AS HORMONE RESPONSES TO 
EXERCISE TRAINING. YOU WILL BE GIVEN A STANDARD TRAINING PROGRAM 
INDIVIDUALIZED IN ACCORDANCE WITH THE COMBINED RECOMMENDATIONS OF AN 
EXERCISE PHYSIOLOGIST AND A MEMBER OF THE RACING SOUTH COMPETITIVE 
TEAM (GUESS WHO). MIKE CALDWELL, COACH OF WORLD-CLASS MARATHONER 
BENJI DURDEN, HAS ALSO AGREED TO PROVIDE CONSULTATION. 
IN ADDITION TO THE REQUIREMENTS STATED ABOVE, SUBJECTS MUST 
BE NONSMOKERS, NONUSERS OF ORAL CONTRACEPTIVES, AND FREE OF METABOLIC 
DISEASE. THE STUDY IS SCHEDULED TO BEGIN IN NOVEMBER. FOR MORE 
INFORMATION CONTACT ME OR DR. TERRY BAZZARRE AT THE NUTRITION DEPART­
MENT AT UNC-G (379-5332) OR CALL 275-4220. 
THANKS 
JEANNIE M. CRANE, RD, MPH 
PHD CANDIDATE, UNC-G 
(RSCT) 
S I I I N S I O I O ,  N O R T H  C  A  *  O  1 1  N  A  /  J 7 4 1 2 - 5 0 0 1  
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THE UNIVERSITY OF NORTH CAROLINA 
AT GREENSBORO 
Schooi a) Homa Ecunomtci 
Dtpanrntml of Ftfd l̂iuruw*-Fa»d Stmt* 
t0!01 379-5332; 5313 October 21, 1983 
PUBLIC SERVICE ANNOUNCEMENT 
WOMEN RUNNERS are needed to participate in a 5-fflonth study being conducted at 
the University of North Carolina at Greensboro. Runners must be 18-35, nonusers 
of oral contraceptives, and currently running 15-25 miles per week. For more in­
formation, contact Or. Terry Bazzarre or Jeannie Crane at 379-5332. 
RELEASE DATE: MEDIATE ENO DATE: NOVEMBER 28,1983 
CONTACT: JEANNIE CRANE OR TERRY BAZZARRE ; 379-5332 or 275-4220 (evening) 
UNIVERSITY OF NORTH CAROLINA-GREENSBORO 
DEPARTMENT OF NUTRITION 
GREENSBORO, NC 27412 
C*CS1VSII0«0. NORTH CltOll."**/27JII-JOOI 
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TELEPH1E SCREENING QgSTUNWPE 
NAME DATE 
ADORESS 
PHONE (H) 
(W) 
(+) f-J 
YES NO 1. Do you live In the Greensboro area? 
YES NO 2. Are you between the ages of 18 & 35? What 1s your birthdate? / / 
a d y 
NO YES 3. Oo you saoke tobacco? 
NO YES 4. Are you currently taking OCA or have you, within the past 6 months? 
- Any other abdications? {If yes:) What? __________________________ 
S. Have you had or do you now have any of the following Illnesses or disorders? 
NO YES Diabetes 
NO YES Heart disease 
NO YES Hypertension 
NO YES Pituitary disorders 
NO YES Menstrual Irregularities 
YES NO 6. Has yourmenstrual period been quite regular within the last 6 months? 
How often do you usually get your period? ______________________ 
YES NO 7. Are you currently running between IS t .25 miles per week? 
How much do you usually run per week? ______________ 
Describe - generally - your workouts during the past 6 months: 
What other exercise do you do now, or have you done in the past 6 months on 
a regular basis? ________________________________________ 
NO YES 8. Have you been on any special diet within the past 6 months? 
e.g., veget hi-pro other 
wt loss low-cho specify 
YES NO 9. Would you be willing to run as your ONLY form of exercise for 6 months? 
YES NO 10. Would you be willing to stop eating meat, fish, & poultry for 6 months? 
APPENDIX B 
LETTER OF CONSENT 
t N F O R M E O  C O N S E N T  
I agree tp participate in  the study antltled "Nutritional Status and Reproductive Hormone Re­
sponse of Feaales Participating In * 6-Month Exercise Program." I r«al 1z« that ay participation In 
the study will be required through 7 of ay aenstrual eye lis, which Is anticipated to l>a 6J to 7 
aontfts. Tha rasaareh Is bain? conducted by Or. Tarry Sazzarra, Sr. Michael Uebman, and Jaannla 
Crana. Othar Investigators Include Henry Trolllngsr, Bonlta Irvln, and Vangle Foshee. 
( understand that the purposes of the study are to deteralne.(t) dietary patterns aaong woaen 
runners contusing a lacto-ovo vegetarian d1tt; and (21 plasaa lipid and mineral responses, as well 
as reproductive horaone responses to exerclsa training. 
Prior to tha 6-month training prograa I.will provide 2 fasting blood saaples of IS al aach and 
a 3-day food record, t realize that a fasting blood 3asp Is will also be required on one day of ay 
3rd, Sth, and 7th aenstrual period during the study. 
At bath the beginning and end of the 6-aonth training period I will cooperate In the following 
procedures: (l)a lS-al blood drawing every other day between the 10th day and last day of ay aen­
strual cycle: and (2) a treadalll test of aaxlaal oxygen uptake. I understand that I will be required 
to provide Information regarding ay aenstrual, aedlcal, athletic, and dietary history. In addition, 
I will be asked to coaplete psychological questionnaires. 
I realize that the study Involves 4 tast periods of 7  days each, during which t will provide 7 ,  
24-hour urine saaples and 7, 24-hour records of food Intake and activity. During the 4 test periods 
I will also cooperate in aeasureaents of percent body fat, height, and of resting aetaboMc rate. 
The latter requires that on 2 separate days ( report to the Huaan Performance Laboratory at UNC-S 
laaedlately after arising In the aornlng, after a 14-hour fast. 
I understand that I will be required to abstain froa flesh foods (aeat, fish, poultry) froa at 
least 3 days pre-study until coapietlon of the study, and that 1 will be counseled by a registered 
dietitian with regard to aenu design for a lacto-ovo vegetarian diet. 
I understand that t aay experience discomfort at tlaes, associated with physical exartlon, al­
though tha training prograa I follow will ba modified according to ay Individual needs, and will be 
carefully aonltored by the Investigators so as to reduce risk of injury. Potential risks involved 
In the study Include venipuncture ( I.e., bruising. Infection, air taboll) and Injury due to running, 
t realize that all precautions have bean taken to alnialze these risks (e.g., use of only highly 
trained personnel and established protocols}, and that I can voluntarily withdrew froa the study at 
any tlae of ay choosing without Incurring prejudice froa the Investigators. 
The benefits I aay gain froa the study include evaluation and laproveaent of ay diet, fitness 
level, running perforaence, and body composition. I can also expect to learn about exercise training 
principles; physiological response to exercise; nutrition; and ay own blood lipid and selected mine­
ral levels. Another potential benefit Is group support and motivation to carry out my exercise prograa. 
t understand that Or.Bazzarre, Or. Llebaan, Jeannle Crane, or any meatier of the Investigative 
staff will ba available to answer questions thet I aay have regarding the study. They aay be reached 
at the UNC-G Nutrition Oepartaent on weekdays at 379-5332. All of ay laaedlate questions have been 
answered. 
•wnTTwrrrgmnwr 
witness signature date 
APPENDIX C 
PRE STUDY AND POSTSTUDY QUESTIONNAIRES 
Ill 
NAME 
PERSONAL DATA 
ADDRESS_ 
1. Oate: / / 
IT 3 y 
2. Blrthdate: / / PHONE (H) (W)_ 
~~m 3 y 
3. Education: Place a check beside the highest level of education completed. 
Hlqhschool Batchelor's (+) JO 
High school (+) Master's MO or DOS 
Batchelor's Master's (+) PhO 
4. Occupation: Please check the appropriate space. 
Teacher/Educator/Student Attorney/Scientist/Engineer 
Secretary Phys1c1an/Nurse/Health Professional 
Administrator/Executive Artist 
Journa11st/Edltor Market1ng/Sa1es/Advert1si ng 
Homemaker Other 
' (please specify) 
ATHLETIC HISTORY 
S. Check the corresponding column Indicating the frequency with which you participate 
in any of the following sports. (If no participation, leave blank.) 
4-7 days/wk 1-3 days/wk occasionally (mi./wk) 
1) Running ________ 
2) Swimming 
3)Bicycl1ng 
4) Dance __________ 
5)Tennis/Squash/Racquetball 
6)Walking 
7)Basketbal Wolleyball 
8)Field Hockey/Soccer 
9)Skating/Skiing 
10Weight training 
IDOther: 
(specifyj 
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Please write your sports in order of amount of participation (* 1, most active, 
etc.). Write in the box the number of the sport as listed on the previous page, 
as well as the name of the sport. 
Sport #1 
name or sport 
Min./day in training __ 
Days Art _____ 
Wk/yr 
Age at onset of training 
Years in training _____ 
No. of breaks in training/yr _____ 
Avg. duration of breaks weeks 
No. of competitive events in 1983 
in 1982 
7. Sport n | | 
name of sport 
Mln. /day in training ____ 
Days/** _____ 
Wk/yr 
Age at onset of training 
Years in training _____ 
No. of breaks in training/yr _____ 
Avg. duration of breaks weeks 
No. of competitive events in 1983 
in 1982 
Racing History: 
3. No. of 10-KUI races completed in 1983: 
9. No. of other races completed: 
1983 
Distance No. Completed 
in 1982: 
Distance 
1982 
No. Completed 
10. Personal best times achieved: 
Distance Time Date Run 
10 km ( 6 . 2  m i )  
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MENSTRUAL HISTORY 
11. At what age did you have your first menstrual period? years 
12. Do you have any history, of menstrual dysfunction or irregularities? yes no 
If yes, explain: ________________i>_____i____i__^____ 
13. Do you now have regular menstrua 1 periods? yes no 
If yes: 
14. How frequently? 
15. How many flow days? ______ 
16. Usual course: painless 
(check one) with cramps 
varies; explain: 
17.Date of onset of last menstrua! period: / / 
m a y  
18.Has there been a change in your menstrua7 cycle since you started running? 
yes no 
If yes, what? 
Does this pattern change if you stop running or run irregularly? yes no 
If yes, how? ________________________________________________ 
Ooes this pattern resume when you begin running again? yes no 
If yes, how long does it take? 
19.No. of pregnancies: ________ 
No. before starting training _____ 
No. after starting training _____ 
20.Are you taxing birth control pills? yes no 
If yes, when did you start? • 
21.If you are a former BC pill user, when did you take then? 
/ until / / until / 
mo yr IIO yr ; no yr mo yr 
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MEDICAL HISTORY 
22. Do you have or have you had any of the following diseases? 
Coronary heart disease Amenorrhea 
Hypertension Hypothalamic-pituitary disorder 
Diabetes Hyperlipidemia 
Hyperpro1act1nemi a Anemia 
Please Indicate your smoking , drug, and alcohol status: 
23. 
24. 
Tobacco use: 
Alcohol use: 
25. Marijuana use: 
jiever; _stopped ( years ago); yes, packs/day 
jiever; yes: beers/wk 
wine/wK 
1 iquor/wK 
never use it; yes: _once/wk or more 
1-3 timea/mo 
fewer than once/mo 
26. Are you on any Medications? 
if yes: name 
_yes no 
Oosage and frequency 
27. Do you take vitamin or mineral supplements? yes no 
If yes: What kind When started Frequency taken 
28. Do you follow a particular diet? 
If yes: vegetarian 
low calorie 
low fat 
low carbohydrate 
yes no 
high protein 
high carbohydrate 
low sodium 
other; please specify: 
29. Oo you take any other dietary supplements? 
If yes, please specify: 
yes no 
Page 5 of 5 
30. Have you lost weight since beginning training?- yes no 
If yes: How much? 
When? 
In how long a period of time? _____ 
31. Has your diet changed since you started training? yes no 
If yes, when? 
In what way? 
32. Indicate your normal consumption during the past 6 months of the following: 
< 1/wk 1-2 X wk 3-5 X wk 6-10 X wk > 10/wk 
Red meat (beef, pork, lamb)... 
Poultry 
Fish 
Milk; Whole 
Low-fat 
Skim _____ ______ ______ ________ 
Buttermilk _____ _____ _______ _____ 
Yogurt; Whole-milk 
Low-fat 
Icecream 
Eggs 
Cheese ______ ______ ______ ______ 
Specify type(s): 
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WOMEN RUNNERS RESEARCH NAME 
POST-STUDY QUESTIONNAIRE 
ATHLETIC HISTORY 
1. Check the corresponding column indicating the frequency with which you partcipated 
in the following sports during your involvement in the Women Runners Study. (If 
no participation, leave blank.) 
4-7 days/wk 1-3 days/wk occasionally (mi,/wk) 
1) Running 
2) Swinurvng 
3! Bicycling 
4) Oance 
5) Tennis/Squash/Racquetball ____ 
6) Walking 
7) Basketball/Volleyball 
3) Field Hockey/Soccer 
9) Skating/Skiing 
10) Weight training 
U) Other: __________ 
I specify) 
2. Please list any races and corresponding times that you completed since the 
beginning of your participation in the Women Runners Study. Please star (*) any PRs. 
Distance Time Date Run Distance Time Date Run 
MENSTRUAL HISTORY 
3. Since your participation in the Women Runners Study, what has been the usual number 
of flow days of your menstrual cycle? 
4. Usual course: painless 
(check one) 
cramps 
varies; explain: 
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5. Has there been any change in your menstrual cycle since the beginning of the study? 
If yes, what? ^____________________ 
Please indicate your smoking, drug, and alcohol status: 
6. Tobacco use: never; stopped { years ago); yes, pks/d\ 
7. Alcohol use: never; ______ yes: beers/wk 
_____ wine/wk 
1iquor/wk 
8. Marijuana use: never; yes: once/wk or more 
1-3 times/mo 
_____ fewer than once/mo 
9. Have you been on any medications since the beginning of the study? yes no 
If yes: Name Oosage & frequency Dates started/stopped 
___________ __________ /' 
/ 
/ 
10. Oo you take any vitamin or mineral supplements? yes no 
If yes: what kind when started frequency taken dosage (if known) 
11. Do you take any other dietary supplanents? yes no 
If yes, please specify type of supplement, quantity, frequency, and wfien started: 
12. In ttie 6 months prior to the beginning of the study, did you experience any changes in 
body weight? ______ yes no 
If so: lost lb./gained lb. 
when: to 
(date) (date) 
lost lb./gained lb 
when: to 
(date; (date; 
Page 3 
Indicate your normal consumption of the following foods since the beginning of your 
participation in the Women Runners Study: 
1/wk 1-2 x wk 3-5 x wk 6-10 x wk 10/wk 
Red meat (beef, pork, lamb).. 
Poultry 
Fish _____ 
Milk: Whole 
Low-fat 
Skim _____ ______ _____ _____ 
Buttermilk 
Yogurt: Whole milk 
Low-fat 
Ice cream 
Eggs 
Cheese 
Specify type(s): 
APPENDIX D 
INSTRUCTIONS FOR THE 24-HOUR FOOD RECORD 
INSTRUCTIONS FOR A FOOD RCCORO 
Thtst Inttrucffans alii htlp you in recording tot food t>i«t you tat. Mease road these instruc­
tion* carefully. If you have any Questions. alias* feel free to call tht Oeoartaent of rood* 
and Nutrition at the University of north Carolina at Greensboro, J79-S332 or J79-SJ1 J. 
1. Measure «acn <taa using household aeasureatnts (cuo. i eup, 1/3 cue I/* cup. tablespoon, 
teasooon, 1/4 teaspooa, t/2 teaspoon, 1/4 teespoon, ate.). Abbreviations can bo usod. 
C<cup 
T« Tablespoon 
t* teaspoon 
2. For fttas that art not Mtasurtd such <1 fresh fruit or *49*. aritt tht nuabtr of Itm tatan 
and whether thty art targe or saalt. 
Ciaaoles: 
1 targe agg 
I mil banana 
J luaps sugar 
Additional inforaetlon about tht sizeef the food such as diaatttr, length, aidth, thlckntss or 
ounce* Is helpful. 
£xtaplee: 
J* carrot 
I 8ro««1e alth aeinuts, aedge 2* by 2* by I* high 
t - 12 ox. can Coke 
Pizza with aushroen, green pepper and cheese • t/S of 12" pizza 
1 apple - 2 1/2 * dleaeter 
1. If you da net tat aU the feed you hate served on your plate, try to Measure the aaount of 
«ach ttea yea did net tat and subtract that aaaaat from abet hi served. 
Ciaaile: If yea are served a peanut butter SMdalch alth tae slices of bread and 2 T paanut 
butter and yea eat 3/4 of the sandalch, yea have eaten t 1/2 sMcee of bread and t t/2 T of 
peanut butter. 
4. Otscrlbt the toed eattn at tiactly as possible 
&• For aeet fish, poultry and eggs specify the cut or type of aeat or fish (chuck or bass), 
•nether you ate or triaaed off the fat, ahether you ate the skin (poultry), percent fat 
(haaburger) and another the fish aat oil pack or attar pack (tuna). 
b. For breads, eertal, cakes, cookies, etc. state another the rood 1s Made froa ahltt flour 
or anele grain and ahether the food aas hoaeaade or bought. Sptcffy tht brand naats «nene»er 
possible. 
c. For Margarine state the brand naae,ahether tht Margarine coats as 1 stick, soft ar Mould, 
•nether It (s dltt or rtgular and ahtthtr 1t Is ahipptd or not* 
d. For oils and shortening statt tht brand naae. the Major oll(s) (if known) ind «ntthtr 
tne 'at is solid fat or oil. 
a. For salad dressings sptclfy ahtther it is hoaeaade. coaaercial or restaurant, the typt of 
ait ar brand naat. crtaay or cltar, and additional ingredients such as cheese or bacon bitts. 
f. For dairy products indlcatt tht percent fat, tne brand naae or rtlativt price and oflttner it 
is a true dairy product or a nondairy product. 
g. For bakery itaas state ahether they are hoaeaade, rtstaurant or coaatrcial, tne brand, tht 
principal fat, tappings or frostings, yeast or cake and type of grain. For pits indicatt 
ahtthtr it is a single or daub It crust. 
n. Far saucts and gravits indlcatt tht type of fat, the moat fat and *nat kind of milk added, 
i. For redpis and alatd dishts indlcatt ahtthtr it is hoMtnadt, coaatrcial ar restaurant, 
:nt brand naat. cooking mtthod and alt ingrtdltnts ustd. Subait a recipe if possible. 
j. For fruits and juices indicatt ahtthtr Chty art frtsh, f r o z t n ,  canned, csoktd o r  dritd; 
and ahtthtr tht food is sattttntd or unsattttntd. 
ft. For vtgttablts state ahtthtr tfcty art coofctd or raw, the kind of fat addtd if any, saucts 
addtd, tht atthod cooked and any seasonings addtd. Sptclfy how mashed potatoes «trt prepared. 
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1.  For  soups spaadfy anathar thay art hoawnada ar eannad, ertin soups ar clur soups and tha 
•a tar or kind of •Ilk or stock added. 
a. For bavaragas and cartals, indlcatt ahathar they arc swaatanad or unsaaattnad, dlat-
saactanad or uns»aatanad. tha brand, dacaffalnatad (coffca or tail, and aftatnar It 
is a cola or noncola. 
n. Tor crackers, snacks, candy bars indicate the brand, aeight , typa or site. 
If you ara In deuot as to ahathar the information Is needed or not, Includa tha Inforaatlon. 
5. Record accoapanlaents such as gr»»ty, saucas. salad slrnstings. aayonaise, ketchup,avstard, 
seasonings, garnishes, ate. saparataly. Oo not forgot to record sugar, Taaan, craaa. non -
dairy creaaers or flavorings that you aay add to drinks sued as coffaa. t»as or at Ik. If you 
drink any liquid other than aater, aeasure tha aaount In a liquid (pyrei) measuring cup. 
Or If yau usa the sam cup or glass oftan, Measure tha aaount of liquid tha glass or cup will 
hold and fit! ta tha saaelevel aith tha bavaraga. 
6. Describe how tha food «*s prepared, tncludlng any additional fat. sugar or condiments that 
aay ba addad. 
Exaapla: 
sautaad <n buttar 
bastad *1th garlic buttar 
bollad In water 
daap fat frlad in paanut oil 
siaaered In «<n« 
7 .  Oo not forgot to racord snacks. If you aat a snack aaay froa hoaa carry tha arapplng hoaa 
•1th you as a raalndar. 
APPENDIX E 
ACTIVITY RECORDS 
DAY NO. 
NAME 
lasS first 
OATE / / 
m "3 y 
SUBJECT ID 
Write in the space provided 
the categorical value which 
corresponds best to the 
dominant activity of each 
15-nrfnute period. Please 
consult the activity card 
to establish proper coding. 
In case of doubt, make a 
note and raise the problem 
during the interview. 
Suamary 
1- 2« 3* 
4* 5- 6" 
7* 3- 9-
Table of activities, energy costs, and corresponding 
categorical values* 
Categorical Examples of activities 
value 
1 Sleeping 
Resting in bed 
2 Sitting: eating, listening, writing, etc. 
3 Light activity standing: washing, 
shaving, combing, cooking, etc. 
4 Slow walk (<4 km/hr), driving, to 
dress, to shower, etc. 
5 Light manual work: floor sweeping, 
window washing, driving a truck, 
painting, waiting on tables, 
nursing chores, several house 
chores, electrician, barman, 
walking at 4 to 6 km/hr 
6 Leisure activities and sports In a 
recreational environment: baseball 
golf, volleyball, canoeing or 
rowing, archery, bowling, cycling 
(<10 km/hr), table tennis, etc. 
7 Manual work at moderate pace: mining, 
carpentry, house building, lumbering 
and wood cutting, snow shoveling, 
loading and unloading goods, etc. 
8 Leisure and sports activities of higher 
Intensity (not competitive): canoeing 
(5 to 8 km/hr), bicycling (>15 km/hr), 
dancing*, skiing, badminton, gymnastic, 
swimming, tennis, horse riding, walking 
(>6 km/hr), etc. 
9 Intense manual work, high Intensity sport 
activities or sport competition: tree 
cutting, carrying heavy loads, jogging 
and running (>9 km/hr), racquetbail, 
badminton, swimming, tennis, cross 
country skiing (>8 km/hr), hiking and 
mountain climbing, etc. 
*from Bouchard et al., 1983 
Energy cost In mets from 
various studies Median energy cost used 
Minimum Maximum METS kcal/kg/15 
mln 
1.0 1.0 0.26 
1.0 2.0 1.5 0.38 
2.0 3.0 2.3 0.57 
2.0 4.0 2.8 0.69 
2.3 5.0 3.3 0.84 
3.0 8.0 4.8 1.2 
4.0 8.0 5.6 1.4 
5.0 11 6.0 1.5 
6.0 ~15 7.8 2.0 
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APPENDIX F 
SAMPLE TRAINING SCHEDULE AND RUNNING LOGBOOKS 
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TMINIM SCWBUU rCINIMLOfir 
n Maarata paca. 
Q...-. 4*1ct paca (hard offort). 
E Casy pact; »ory cnfertult paca fop mi t«i Is Mi sum u '}a<f.' 
Surqa A NQA I* a 4 aaea tltratat »• dartaf a COHCIMMMS rtm FOR a ««T dlstanca or t1aa. 
FartlaH (Pk)...(*3paad»lay*): A caatUatlaa of raaatn* »•<<! (vary sloa (o vary fast); Ooaa as a continuous 
raa alt* tiw distancas of tiw dlfforaat ipaads also varying. 
Stridors M>4S1 of aaslawl affart. Stridors art usually 50-100 a loaf t ara froqaMCly part of tiw 
a. H for a (rack vortoat or a raca, I ara tnallaai practiced at tlw and of a aartoat. 
Stridors Halp to toasaa * ta Mtarally "vara uf* aasclas. Also asaful for balldlnq I09 tpoad. 
MST. UST, K(STI This aasss NO RUMtK. Ma, not »«oa aa C mat 
tf. up ....Mar* m. Far a eoatlaaaas na, a. aa caastftatas raaalaf Uoqgtoql at a (Mfartitla oaet for 
yaa. ti. « for t spaod or track aarkoat aay ta qaita dlfforaat t dapondoat oa tlw typo of 
lasslea ta foltoa. 
Coal Mm £ paca raa. 
laddor Prafrasstvaly iacraailai (or Mrmintl dlstsacas or tiaas. o.g.. 200. MO, 600, MO a on tna 
track, or iirfii of 1, ],],!« almtcas, A Pack dam tlw I a Mar; a, J, 2. 1. 
M.. Haart (p«lsa) rata. 
Accalarata fruwislwly tncraasiaf ipoad o«ar tlw oatlra dtstaaca spaclflod, ta acealarata oaar l 
alia aaam tkat yaar paca ly t a1 la is fastar tMa at i art la, a*1ck is aaek faster tftaa your 
paca aos at i alio. 
Oacalarata (1 tMak yaa eaa fljara tkls oa* oati) 
S.t.l (SnM of Llqftt): AI1«oat or raca paca. 
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NAME 
Week 
(Date) 
6 
( i/t- 3/, ?•) 
( V'f'i/ii) 
X  
(¥*r- J/JI ) 
Comments: 
( 1) 2 (J, ; / •*%* (j) • [ -^u' y / i Z. >«-» • 
( 2 )  / • ?  p * c * . u u * f C f i r  / Q X / O C - r \  & U v s  
?  I  
( 3 )  Z  * M C I  C J . - T ' ;  V >  Z O O " A  S J W A / T W ;  Q  Z 1 * *  > « J .  C A ^ D O U M . .  
[  4)  sot. XuxsntiJ /r®"'*" n*w*' / yoc< » ay l^o «f nXTti* 4  <-£' "*• • 
uerko*j\ (0*9. ftcj*. cLb^r s*tj*J~r to L*- a »^er/ f£e*+jk •) 
( 5 )  ^ i x J L f  r u c > v .  :  < ^ . c f l u  s / ^ -  C »  U * S L $ J  t  G O - *  ̂ 0 0  A f  d o * * ^  .  
(^j .2 "•** uJ-^o ; 2*w"; C O »«•«•' ; 21 "Hi coe^down-
( 7 )  
NOTE: 
Workout 
s M T W Th F S 
'2. s* * yaj y ,? 
//"> r /" * ? ?<6/ 6, 
I f -  G ^  
"> « + +*> T 
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OATE C> -/O 
DISTANCE^ 
TIME 
2. 
DATE L 
DISTANCE_ 
TIME 
-/A 
a 
HEART RATES 
(and at which 
points taken 
during run) 
( 
) 
HEART RATES 
(and at which 
points taken 
during run) 
REMARKS (shoes, course, pain, etc.) 
"  J £ / ? / + » • >  a/ / X n  
4/̂  OJ- /. c* r- /OtldT 
(J" J' /&-* M VJ-^LS 
e*4 y c/',A.t 7 *AU„ A Sa 
Ch / J  m u ^ / n m +  _ 
o/a 7 n*-d 
Plu 7+U my ,f7) AcLLAI+I _ 
fex/Ut̂  +<iA£f  ̂ LAtt*i-4 m* IniL- _ 
O^TE 
0ISTANCE it ZV*. Taac.lt>. 
TIME SSULG*B*xJ 
REMARKS (shoes, workout, weather, etc.) 
*-
"b-dc. 
HEART RATES . ( , 
(and at which 
points taken ^9^ ( 
during run) 
( 
DATE C/.;.j)e-a^ 
DISTANCE ?n„^ (tnd. 
TIME I irv\ iZ-OhiO __ 
HEART RATES 1-6> 
(and at which 
points taken 
during run) 
( •%,»».)<& ) 
( 
REMARKS (shoes, course, pain, etc.)_ 
IV2. u>J .ia • 
REMARKS (shoes, workout, weather, etc.) 
fY a 
n f l -
*4<40 
1 >H i t 1 '• M? 
suo 2°% 
^ n , ; n  t • u2 
—% 
^  r t i J t  I  -  V  ̂  
V J. 0 j 
C X  r t u u f ^ . T f .  
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DATE 7-1 
7-3-'. 
DISTANCE 1,0 
TIME 1: IS :iM 
HEART RATES J.-& ( PmA ) 
(and at which 
points taken ( ) 
during run) 
( J 
REMARKS (shoes, course, pain, etc.) Jl 
DATE 7 - .3 
DISTANCE L . n  
TIME S3". 1Q 
HEART RATES Jtc 
(and at which 
points taken 
during run) 
< l 
) 
REMARKS (shoes, workout, weather, etc. 
CA M V biSuM?, L\jJ- 4 — 
i4- 4o 
4 i4r AmP ^V^OC, 
*tAsy 
(XUj  (lluijrsh >kiM, — 
j LbdJ^ Uojfhcfi yfn 
L'l*_ 4P CU^~ 
DATE 
01 STANCE //,«., 
TIME / •• •<? 
HEART RATES 
(and at which 
points taken 
during run) 
0? J7 (. 
REMARKS (shoes, course, pain, etc.) 
jp&£&L. X 
PATE 
01STANCE z' 
TIME jt-1 
HEART RATES 
(and at which 
points taken 
during run) 
( 
REMARKS (shoes, workout, weather, etc.) 
f ) ; 4  *iaJ~ •j---' g 
Q(lO-l±r>cQ Aarr/e yr Priori ate a. ft a.t>t 
T1 /w <s> <•>/« 
/Jan vJiP (L iiu,** 6 
buJ—^LsLil <2-t>r fefS dm-r»r- Q?fn,} 
£AsLS£L <\ 3. jr. 
-Hi t***K JSn. L J0mi is i <=> 
"7" SmtJ "7T 
StvpjFr 4 ^ *.t 
APPENDIX G 
INDIVIDUAL HORMONE DATA 
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LH PROG 
mill/ml ng/ml 
44 22 
40 20 
36 18 
32 16 
28 14 
24 12 
20 10 
16 8 
12 
8 
4 
0 
SUBJECT 01 
PROG 
os LH 
=TP I 
=TP IV 
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 
DAYS OF CYCLE 
Serum LH Plasma Progesterone,Test Periods I and IV 
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Serum Luteinizing Hormone (LH) and Plasma Progesterone (P)a 
Test Period I Test Period IV 
Subject 
1 
Cycle LH P LH P 
Day mlU/ml ng/ml mlU/ml ng/ml 
9 7.2 1.2 
10 (1.2) 10.9 0.3 
11 7.8 1.1 (0.6) 
12 (1.3) 10.6 0.9 
13 24.2 1.5 (0.8) 
14 (2.6) 19.7 0.6 
15 9.7 3.6 (0.8) 
16 (9.8) 13.5 0.9 
17 6.6 16.0 • (2.0) 
18 (12.7) 12.2 3.1 
19 4.2 9.4 (3.1) 
20 (8.5) 13.9 3.0 
21 2.0 7.5 (2.3) 
22 (4.9) (1.6) 
23 5.2 2.3 7.2 0.9 
24 (2.9) 6.0 0.5 
25 5.3 3.5 
26 
27 
28 
29 
30 
aValues in parentheses represent estimates based on measured values 
of preceding and subsequent days 
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LH PROG 
mIU/mi ng/ml 
44 22 
40 20 
36 18 
32 16 
28 14 
24 12 
20 
16 
12  
8 
4 
0 
10 
8 
6 
4 
A= PROG 
o= LH 
SUBJECT 02 
=TP I 
=TP IV 
... = Estimated 
Values 
>—A A 
...A,—*—± A"' 
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 
DAYS OF CYCLE 
Serum LH Plasma Progesterone, Test Periods I and IV 
134 
Serum Luteinizing Hormone (LH) and Plasma Progesterone (P)a 
Test Period I Test Period IV 
Subject 
2 
Cycle LH P LH P 
Day mlU/ml ng/ml mlU/ml ng/ml 
10 8.4 1.4 (0.2) 
11 (1.6) 13.7 0.2 
12 9.6 1.7 (0.3) 
13 (1.4) 12.8 0.3 
14 16.6 1.1 (0.3) 
15 (3.0) 13.5 0.3 
16 (4.9) (0.3) 
17 11.9 6.7 (0.3) 
18 11.9 9.6 (0.2) 
19 (12.8) 80.7 0.2 
20 9.8 16.0 (0.4) 
21 (16.0) 13.6 0.5 
22 (16.0) 16.3 0.9 
23 3.6 16.0 (0.9) 
24 6.4 16.0 13.7 0.9 
25 (16.0) (1.0) 
26 10.8 16.0 11.5 1.0 
27 (8.8) 
28 5.7 1.5 
29 
30 
aValues in parentheses represent estimates based on measured values 
of preceding and subsequent days 
135 
LH PROG SUBJECT 03 
mlU/ml ng/ml 
A= PROG =TP I 
44 22 o= LH =TP IV 
= Estimated 
40 20 Values 
36 18 
32 16 
28 14 
24 12 
20 10 
16 
12  
8 
4 
0 
8 
6 
4 
2 
0 
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 
DAYS OF CYCLE 
Serum LH Plasma Progesterone, Test Periods I and IV 
136 
Serum Luteinizing Hormone (LH) and Plasma Progesterone (P)a 
Test Period I Test Period IV 
Subject 
3 
Cycle LH P LH P 
Day mlU/ml ng/ml mlU/ml ng/ml 
10 7.1 0.4 6.2 0.4 
11 (0.3) (0.3) 
12 6.5 0.2 6.4 0.2 
13 (0.3) (0.3) 
14 9.4 0.3 8.6 0.3 
15 (0.3) (0.3) 
16 6.4 0.3 12.2 0.3 
17 (0.3) (0.3) 
18 10.2 0.3 12.3 0.2 
19 (0.3) (0.3) 
20 7.0 0.3 15.3 0.3 
21 (0.3) 9.5 0.9 
22 8.1 0.2 (1.5) 
23 (0.2) 10.9 2.0 
24 13.8 0.2 (2.5) 
25 (0.3) 5.3 2.9 
26 18.0 0.3 10.8 1.9 
27 (0.5) 
28 5.1 0.7 
29 (0.6) 
30 (0.5) 
31 (0.4) 
32 (0.3) 
33 (0.2) 
aValues in parentheses represent estimates based on measured values 
of preceding and subsequent days 
137 
LH PROG 
mlU/ml ng/ml 
44 
40 
36 
32 
28 
24 
16 
12 
8 
4 
0 
22 
20 
18 
16 
14 
12 
20 10 
8 
6 
4 
2 
0 
N °̂ 
SUBJECT 04 
A= PROG =TP I 
o= LH =TP IV 
—A 
= Estimated 
Values 
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 
DAYS OF CYCLE 
Serum LH Plasma Progesterone, Test Periods I and IV 
138 
Serum Luteinizing Hormone (LH) and Plasma Progesterone (P)a 
Test Period I Test Period IV 
Subject 
4 
Cycle LH P LH P 
Day mlU/ml ng/ml mlU/ml ng/ml 
10 11.0 0.6 24.9 0.4 
11 (0.6) (0.4) 
12 8.5 0.6 34.7 0.3 
13 (0.7) (0.3) 
14 10.8 0.7 33.7 0.2 
15 (0.7) (0.3) 
16 10.5 0.7 42.5 0.3 
17 (0.8) (0.3) 
18 43.1 0.9 40.9 0.3 
19 (1.4) (0.5) 
20 9.1 1.8 27.5 0.6 
21 (3.8) (0.6) 
22 9.7 5.8 27.1 0.6 
23 (4.7) (0.6) 
24 4.3 3.5 24.2 0.5 
25 (2.8) (0.4) 
26 3.9 2.0 (0.4) 
27 (0.3) 
28 (0.2) 
29 
30 
aValues in parentheses represent estimates based on measured values 
of preceding and subsequent days 
139 
LH PROG SUBJECT 05 
mIU/ml ng/ml 
A= PROG =TP I 
os LH -TP IV 44 22 
40 20 
36 18 
32 16 
28 14 
24 12 
20 10 
16 8 
12 6 
8 4 
4 2 
0 0 
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 
DAYS OF CYCLE 
Serum LH Plasma Progesterone, Test Periods I and IV 
140 
Serum Luteinizing Hormone (LH) and Plasma Progesterone (P)a 
Test Period I Test Period IVb 
Subject 
5 
Cycle LH P 
Day mlU/ml ng/ml 
10 9.4 0.4 
11 (0.4) 
12 5.6 0.4 
13 (0.4) 
14 7.1 0.3 
15 (0.3) 
16 20.0 0.3 
17 (0.8) 
18 20.3 1.3 
19 (2.4) 
20 12.5 3.5 
21 (7.3) 
22 4.1 11.0 
23 (10.3) 
24 3.3 9.5 
25 (8.2) 
26 (6.8) 
27 3.6 5.5 
28 6.0 4.8 
29 (3.1) 
30 6.1 1.3 
LH 
mlU/ml 
P 
ng/ml 
aValues in parentheses represent estimates based on measured values 
of preceding and subsequent days 
^Subject became pregnant in Test Period IV; data not reported 
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LH PROG 
mlU/ml ng/ml 
44 22 
40 20 
36 18 
32 16 
28 14 
24 12 
20 10 
16 8 
SUBJECT 06 
12 
8 
4 
0 
6 
4 
2 
0 
A= PROG 
os LH 
=TP I 
=TP IV 
= Estimated 
Values 
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 
DAYS OF CYCLE 
Serum LH Plasma Progesterone,Test Periods I and IV 
142 
Serum Luteinizing Hormone (LH) and Plasma Progesterone (P)a 
Test Period I Test Period IV 
Subject 
6 
Cycle LH P LH P 
Day mlU/ml ng/ml mlU/ml ng/ml 
10 11.5 0.0 9.8 0.4 
11 (0.1) (0.4) 
12 8.7 0.2 5.8 0.4 
13 (0.5) (0.4) 
14 14.9 0.7 6.1 0.3 
15 (0.9) (0.4) 
16 30.1 1.1 29.7 0.4 
17 (1.5) (0.4) 
18 10.2 1.9 15.5 0.4 
19 (3.8) (1.1) 
20 11.3 5.6 9.4 1.7 
21 (6.7) (2.2) 
22 4.4 7.8 7.2 2.6 
23 (6.6) (2.0) 
24 5.6 5.3 4.9 1.4 
25 (4.2) (2.9) 
26 6.0 3.1 4.9 (4.4) 
27 (1.9) (3.7) 
28 6.5 0.6 3.7 (2.9) 
29 (1.6) 
30 (0.2) 
aValues in parentheses represent estimates based on measured values 
of preceding and subsequent days 
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SUBJECT 07 LH PROG 
mIU/ml ng/ml 
44 22 
- =TP I 
- =TP IV 
40 20 
36 
32 16 
28 
24 
20 
16 
12 
/\ 
o 5 - - v °  
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 
DAYS OF CYCLE 
Serum LH Plasma Progesterone,Test Periods I and IV 
144 
Serum Luteinizing Hormone (LH) and Plasma Progesterone (P)a 
Test Period I Test Period IV 
Subject 
7 
Cycle LH P LH P 
Day mlU/ml ng/ml mlU/ml ng/ml 
10 9.9 0.0 7.2 0.4 
11 (0.1) (0.4) 
12 50.9 0.1 12.6 0.3 
13 (0.7) (0.5) 
14 11.7 1.2 25.4 0.6 
15 (2.8) (1.7) 
16 10.3 4.4 7.7 2.7 
17 (5.5) (3.2) 
18 7.7 6.5 8.0 3.6 
19 (6.7) (4.2) 
20 (6.9) 5.0 4.7 
21 (7.0) (3.8) 
22 8.0 7.2 2.8 
23 (4.7) (4.2) 
24 6.1 2.2 5.0 5.5 
25 (1.1) (3.7) 
26b 6.3 0.1 5.5 1.9 
27 
28 
29 
30 
aValues in parentheses represent estimates based on measured values 
of preceding and subsequent days 
^Onset of next menstrual cycle, Test Period I 
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LH PROG 
mIU/ml ng/ml 
44 22 
SUBJECT 08 
=TP I 
=TP IV 
= Estimated 
Values 
40 20 
36 
32 16 
28 
24 
20 10 
16 
12 
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 
DAYS OF CYCLE 
Serum LH Plasma Progesterone, Test Periods I and IV 
146 
Serum Luteinizing Hormone (LH) and Plasma Progesterone (P)a 
Test Period I Test Period IV 
Subject 
8 
Cycle LH P LH P 
Day mlU/ml ng/ml mlU/ml ng/ml 
10 14.3 0.2 (0.2) 
11 (0.3) 9.2 0.2 
12 17.8 0.3 (0.2) 
13 16.7 0.5 13.5 0.2 
14 (0.4) (0.2) 
15 (0.2) 7.9 0.2 
16 20.4 0.1 (0.2) 
17 (0.2) (0.2) 
18 14.6 0.2 34.0 0.2 
19 (0.2) 33.2 0.2 
20 13.7 0.2 (0.5) 
21 (0.4) 17.8 0.8 
22 74.4 0.6 (0.8) 
23 (0.7) 7.1 0.8 
24 9.0 0.8 (2.9) 
25 (2.4) 4.9 
26 (4.0) 4.2 (3.9) 
27 6.3 5.5 2.8 
28 (4.9) (2.4) 
29 (4.3) 2.7 1.9 
30 (3.7) (1.7) 
31b (3.1) 8.4 1.5 
32 (2.5) 
33 (1.9) 
34 (1.3) 
35 (0.7) 
36 (0.2) 
aValues in parentheses represent estimates based on measured values 
of preceding and subsequent days 
bonset of next menstrual cycle, Test Period IV 
147 
LH PROG 
mill/ml ng/ml 
44 22 
40 20 
36 18 
32 16 
28 14 
24 
20 
16 
12 
8 
4 
0 
12 
10 
8 
6 
4 
2 
0 
SUBJECT 09 
A= PROG 
os LH 
sTP I 
-TP IV 
= Estimated 
Values 
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 
DAYS OF CYCLE 
Serum LH Plasma Progesterone, Test Periods I and IV 
148 
Serum Luteinizing Hormone (LH) and Plasma Progesterone (P)1 
Subject 
9 
Test Period I Test Period IV 
Cycle LH P LH . P 
Day mlU/ml ng/ml mlU/ml ng/ml 
10 8.5 0.8 6.7 0.7 
11 (0.9) (0.8) 
12 7.6 1.0 7.2 0.8 
13 - (1.0) (0.8) 
14 8.0 1.0 5.7 0.7 
15 (1.1) (0.9) 
10 8.6 1.1 7.6 1.1 
17 (1.1) (0.9) 
18 (1.0) 22.5 0.7 
19 9.3 1.0 (1.0) 
20 9.0 1.0 (1.3) 
21 (1.3) 8.9 1.6 
22 35.8 1.5 7.2 2.9 
23 (2.4) (3.0) 
24 10.4 3.2 3.4 3.0 
25 (5.6) (3.6) 
26 7.3 8.0 3.6 4.2 
27 (8.0) (2.9) 
28 5.9 8.0 5.6 1.6 
29 (8.0) (1.5) 
30 5.9 8.0 4.1 1.4 
31 6.7 
32 5.3 5.4 
33 (2.8) 
34 5.0 (0.2) 
aValues in parentheses represent estimates based on measured values 
of preceding and subsequent days 
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LH PROG 
mIU/ml ng/ml 
44 22 
40 20 
36 18 
32 16 
28 14 
24 12 
20 10 
SUBJECT 11 
16 
12  
8 
8 
A= PROG 
os LH 
=TP I 
=TP IV 
= Estimated 
Values 
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 
DAYS OF CYCLE 
Serum LH Plasma Progesterone, Test Periods I and IV 
150 
Serum Luteinizing Hormone (LH) and Plasma Progesterone (P)a 
Test Period I Test Period IV 
Subject 
11 
Cycle LH P LH P 
Day mlU/ml ng/ml mlU/ml ng/ml 
10 (0.2) 7.3 0.8 
11 (0.3) 6.8 0.9 
12 (0.5) 5.8 0.8 
13 6.2 0.7 (1.1) 
14 (1.2) (1.4) 
15 (1.6) 37.7 1.7 
16 (2.1) 11.5 2.7 
17 11.8 2.5 (3.6) 
18 6.6 3.1 5.6 4.4 
19 (7.3) 4.3 8.0 
20 4.1 11.4 (9.3) 
21 (13.7) (10.7) 
22 2.8 16.0 3.9 12.0 
23 (15.2) 5.2 8.5 
24 2.7 14.3 (6.0) 
25 (9.8) 4.1 3.5 
26 1.8 5.3 (2.4) 
27 3.3 1.2 (1.3) 
28 (0.2) 
29 
30 
aValues in parentheses represent estimates based on measured values 
of preceding and subsequent days 
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LH PROG 
mlU/ml ng/ml 
44 22 
40 20 
36 18 
32 16 
28 14 
24 12 
20 10 
16 
12 
8 
8 
6 
SUBJECT 15 
PROG 
o= LH 
=TP I 
-TP IV 
= Estimated 
Values 
; \ / i \ 
\ / i \  i  /  
I b' \\ 
\ty&> 
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 
DAYS OF CYCLE 
Serum LH Plasma Progesterone, Test Periods I and IV 
152 
Serum Luteinizing Hormone (LH) and Plasma Progesterone (P)a 
Test Period I Test Period IV 
Subject 
15 
Cycle LH P LH P 
Day mlU/ml ng/ml mlU/ml ng/ml 
10 8.9 0.5 62.0 0.9 
11 (0.5) (1.0) 
12 11.0 (0.5) 10.0 1.0 
13 (0.5) (6.5) 
14 78.4 0.5 5.7 12.0 
15 (0.7) (7.6) 
16 13.2 0.9 9.0 3.2 
17 (2.1) (2.2) 
18 10.0 3.3 2.9 1.1 
19 (3.1) (1.2) 
20 7.5 2.9 9.3 1.3 
21 (2.4) (1.7) 
22 4.7 1.8 (2.0) 
23b (2.4) 8.0 2.4 
24 4.4 3.0 
25 (1.5) 9.6 
26 (0.2) 
27 
28 
29 
30 
aValues in parentheses represent estimates based on measured values 
of preceding and subsequent days 
bOnset of next menstrual cycle. Test Period IV 
153 
LH PROG 
mlU/ml ng/ml 
A- PROG 
os LH 
SUBJECT 16 
=TP I 
=TP IV 
a—A^a' 
I 
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 
DAYS OF CYCLE 
Serum LH Plasma Progesterone, Test Periods I and IV 
154 
Serum Luteinizing Hormone (LH) and Plasma Progesterone (P)a 
Test Period I Test Period IV 
Subject 
16 
Cycle LH P LH P 
Day mlU/ml ng/ml mlU/ml ng/ml 
10 8.0 1.7 7.4 0.5 
11 (1.8) (0.6) 
12 8.4 2.9 12.7 0.6 
13 (2.3) (0.5) 
14 7.9 3.7 55.7 0.4 
15 (2.8) (1.1) 
16 14.8 1.8 12.4 1.8 
17 (1.7) (2.4) 
18 33.0 1.6 6.2 2.9 
19 (2.7) (3.0) 
20 6.8 3.7 5.6 3.0 
21 8.1 4.6 5.2 2.3 
22 (4.1) (1.7) 
23 6.3 3.5 6.2 1.0 
24 (5.1) (0.7) 
25 3.8 6.7 3.9 0.4 
26 6.8 6.1 
27 (4.7) 
28 5.4 3.3 
29 (2.6) 
30b 8.2 1.9 , 
aValues in parentheses represent estimates based on measured values 
of preceding and subsequent days 
^Onset of next menstrual cycle, Test Period I 
LH PROG 
mlU/ml ng/ml 
44 22 
SUBJECT 17 
- =TP I 
- =TP IV 
A= PROG 
o= LH 
40 20 
36 18 
32 16 
28 
24 
20 
12 
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 
DAYS OF CYCLE 
Serum LH Plasma Progesterone,Test Periods I and IV 
156 
Serum Luteinizing Hormone (LH) and Plasma Progesterone (P)a 
Test Period I Test Period IV 
Subject 
17 
Cycle LH P LH P 
Day mlU/ml ng/ml mlU/ml ng/ml 
10 9.7 0.2 10.9 0.2 
11 (0.2) 11.9 0.2 
12 11.3 0.2 (0.2) 
13 (0.2) 9.2 0.2 
14 10.7 0.2 (0.2) 
15 (0.2) 12.8 0.2 
16 53.6 0.2 (0.2) 
17 (0.2) 32.5 0.2 
18 10.1 0.2 (0.5) 
19 (2.0) 11.9 0.7 
20 10.0 3.8 (0.5) 
21 (3.7) 6.3 0.3 
22 3.4 3.6 (0.3) 
23 (4.5) 4.9 2.0 
24 5.0 5.4 (2.0) 
25 (4.0) 5.6 3.7 
26 3.1 2.6 4.4 2.5 
27 (1.9) (2.2) 
28 3.7 1.2 (1.9) 
29 (0.7) 3.8 1.5 
30 3.8 0.2 (1.1) 
31b 3.0 0.6 
aValues in parentheses represent estimates based on measured values 
of preceding and subsequent days 
157 
LH PROG 
mlU/ml ng/ml 
44 22 
SUBJECT 18 
A=PROG 
o= LH 
- =TP I 
- =TP IV 
40 20 
36 
32 16 
28 14 
24 
20 
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 
DAYS OF CYCLE 
Serum LH Plasma Progesterone, Test Periods I and IV 
158 
Serum Luteinizing Hormone (LH) and Plasma Progesterone (P)a 
Test Period I Test Period IV 
Subject 
18 
Cycle LH P LH P 
Day mlU/ml ng/ml mlU/ml ng/ml 
10 15.0 1.9 12.2 0.2 
11 (1.8) (0.3) 
12 17.4 1.7 54.3 0.3 
13 (2.2) (0.3) 
14 97.6 2.6 19.3 0.3 
15 (2.6) (0.4) 
16 22.1 2.5 7.8 0.4 
17 (3.8) (0.7) 
18 16.7 5.1 8.6 0.9 
19 (6.4) (0.8) 
20 (7.6) 6.1 0.7 
21 (8.9) (1.1) 
22 8.6 10.1 4.9 1.5 
23 (7.8) (0.9) 
24 5.3 5.5 7.9 0.3 
25 (5.2) (0.3) 
26b 8.8 4.8 11.3 0.3 
27 
28 
29 
30 
aValues in parentheses represent estimates based on measured values 
of preceding and subsequent days 
^Onset of next menstrual cycle, Test Period IV 
159 
SUBJECT 21 LH PROG 
mIU/ml ng/ml 
44 22 
A= PROG 
o= LH 
- =TP I 
- =TP IV 
. = Estimated 
Values 40 20 
36 18 
32 16 
28 
12 24 
20 10 
16 
12 
-a 
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 
DAYS OF CYCLE 
Serum LH Plasma Progesterone,Test Periods I and IV 
160 
Serum Luteinizing Hormone (LH) and Plasma Progesterone (P)a 
Test Period I Test Period IV 
Subject 
21 
Cycle LH P LH P 
Day mlU/ml ng/ml mlU/ml ng/ml 
10 (0.2) 8.7 0.2 
11 31.7 1.3 (0.3) 
12 (2.6) 52.3 0.4 
13 13.0 4.0 (0.6) 
14 (5.0) 14.0 0.7 
15 12.8 6.0 (1.2) 
16 (7.5) 8.6 1.6 
17 4.8 9.0 (1.9) 
18 (9.5) 8.3 2.1 
19 6.1 10.0 (2.9) 
20 (10.1) 6.6 3.7 
21 6.8 10.2 (2.9) 
22 (6.7) 8.0 2.0 
23 3.4 3.2 1.5 
24 (1.8) 3.0 0.9 
25 (0.2) (1.3) 
26 5.0 2.7 
27 
28 
29 
30 
aValues in parentheses represent estimates based on measured values 
of preceding and subsequent days 
LH PROG 
mlU/ml ng/ml 
44 22 
40 20 
36 18 
32 16 
28 14 
24 12 
SUBJECT 22 
20 
16 
12  
8 
4 
0 
10 
8 
6 
4 
2 
0 
A= PROG 
o= LH 
— =TP I 
- =TP IV 
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 
DAYS OF CYCLE 
Serum LH Plasma Progesterone, Test Periods I and IV 
162 
Serum Luteinizing Hormone (LH) and Plasma Progesterone (P)a 
Test Period I Test Period IV 
Cycle LH 
Subject Day mlU/ml 
10 
11 23.0 
12 
13 30.9 
14 
15 11.8 
16 11.3 
17 
18 5.5 
19 
20 
21 9.3 
22 
23 7.1 
24 
25 7.1 
26 
27 
28 
29b 
30 
aValues in parentheses represent i 
of preceding and subsequent days 
P LH P 
ng/ml mlU/ml ng/ml 
(0.2) 5.7 0.2 
0.3 (0.2) 
(0.5) 7.4 0.2 
0.6 (0.6) 
(0.9) 22.0 0.9 
1.2 29.5 1.2 
1.7 13.6 1.4 
(3.5) 10.1 3.0 
5.3 6.7 4.1 
11.6 (6.4) 
(6.9) (8.5) 
2.1 5.5 10.8 
(2.4) 5.1 7.7 
2.7 4.7 9.6 
(1.7) (7.6) 
0.6 3.0 5.5 
(3.1) 
5.9 0.7 
(0.5) 
6.1 0.2 
based on measured values 
^Onset of next menstrual cycle, Test Period IV 
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LH PROG SUBJECT 23 
mlU^nl ng/ml 
44 22 
40 20 
A= PROG =TP I 
o= LH =TP IV 
36 18 
32 16 
28 14 
24 12 
20 10 
16 8 
12 6 
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 
DAYS OF CYCLE 
Serum LH Plasma Progesterone, Test Periods I and IV 
164 
Serum Luteinizing Hormone (LH) and Plasma Progesterone (P)a 
Test Period I Test Period IV 
Subject 
23 
Cycle LH P LH P 
Day mlU/ml ng/ml mlU/ml ng/ml 
10 4.7 0.4 6.6 0.2 
11 (0.5) (0.2) 
12 10.4 0.6 (0.2) 
13 (0.6) 8.1 0.2 
14 9.0 0.6 12.1 0.2 
15 (0.8) (0.2) 
16 17.3 0.9 10.3 0.2 
17 (1.0) 8.6 0.8 
18 1.0 (0.8) 
19 (1.1) 15.2 _ 0.7 
20 6.0 1.2 (1.0) 
21 (1.3) 16.3 1.3 
22 23.6 1.3 (2.3) 
23 (1.0) 4.0 3.2 
24 3.6 0.7 (1.9) 
25 3.0 0.6 
26 
27 
28 
29 
30 
aValues in parentheses represent estimates based on measured values 
of preceding and subsequent days 
APPENDIX H 
PROCEDURES FOR DETERMINATION OF 
SERUM CHOLESTEROL AND 
PLASMA ZINC 
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HDL AND TOTAL CHOLESTEROL PROCEDURE* 
1. To centrifuge tube add: 
0.4 ml of serum 
0.05 ml HDL Precipitating Reagent, Stock No. 350-3 
Mix well 
2. Centrifuge (2000 x g) for 5-10 minutes to obtain clear supernatant. 
3. Label 3 or more cuvets in duplicate: BLANK, STANDARD, TEST 1, 
etc. 
4. To BLANK add: 0.05 ml water 
To STANDARD add: 0.05 ml Cholesterol Aqueous Standard, 
Stock No. 350-50 
To TEST add: 0.05 ml Supernatant (HDL fraction) from Step 2 
For determination of total cholesterol include an additional set 
of test samples (in duplicate) containing 0.05 ml aliquots of 
serum, and follow the rest of HDL-C procedure 
5. To each add: 3.0. ml Cholesterol Reagent. Cover cuvet with 
Parafilm and mix well. 
6. Incubate the cuvets at 37°C for 10-15 minutes. 
7. Read Absorbance of STANDARD and TEST vs. BLANK as reference at 
625 nm (_+15 nm). Complete readings within 30 minutes. 
8. Calculate HDL Cholesterol values as follows: 
A 
Serum HDL Cholesterol (mg/dl) = TEST x 55 
aSTANDARD 
* Serum cholesterol was assayed using a Bausch and Lamb Spectronic 
2000 spectrophotometer (Fisher Scientific, Raleigh, NC) with the 
Liebermann-Buchard color cholesterol reagent purchased from 
Stanbio-Laboratory, Inc. (San Antonio, TX). 
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PLASMA ZINC STANDARD PREPARATION 
1. Prepare six standard solutions of 0.0, 0.1, 0.2, 0.3, 0.4, and 0.5 
parts per million (ppm) zinc in dilute sulfuric acid. 
2. Prepare 9.0 liter of a 5.0% glycerol stock solution in an acid-
washed 1.0-liter volumetric flask. 
3. Prepare a 10-ppm zinc working solution in a 100-ml volumetric 
flask by adding 1.0 ml of 1000-ppm zinc standard to 99-ml of 8% 
H2SO4 solution. 
4. From this 10-ppm working solution prepare the concentrations in 
separate 100-ml volumetric flasks: 
a) 0.1 ppm - add 1.0 ml of working solution to 99 ml of H2SO4 
solution. 
b) 0.2 ppm - add 2.0 ml of working solution to 98 ml of H2SO4 
solution. 
c) 0.3 ppm - add 3.0 ml of working solution to 97 ml of H2SO4 
solution. 
d) 0.4 ppm - add 4.0 ml of working solution to 96 ml of H2SO4 
solution. 
e) 0.5 ppm - add 5.0 ml of working solution to 95 ml of H2SO4 
solution. 
f) 0 ppm - bring to volume 100 ml of H2SO4 solution. 
Reference: 
Butrimovitz, G. P., 5 Purdy, W. C. (1977). The determination of 
zinc in blood plasma by atomic absorption spectometry. Analytic a 
Chimica Acta, 94, 63-71. 
